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Diabetes affects approximately 250 million people worldwide and health care
costs related to diabetes equal approximately $98 billion each year. Aldose
reductase has been shown to contribute to the side effects of diabetes
including kidney disease, nerve disease, and retinopathy. Cranberries contain
anthocyanins and other flavonoids that have been shown in vitro to inhibit the
enzyme aldose reductase and to inhibit protein glycosylation. It is believed
that daily cranberry supplementation could reduce side effects of diabetes.

Twenty-seven adults with type 2 diabetes were recruited for this 12 week
double-blind, placebo-controlled study. Fasting blood analysis was done at
weeks 0, 6, and 12. The blood analyses included: cholesterol (total
cholesterol, triglycerides, HDL, LDL, and percent HDL), glycosylated
hemoglobin (HbA, c), blood glucose, insulin, fructosamine, aldose reductase
activity, and hexanal. The subjects were asked to take 6 capsules each day

that contained either spray-dried cranberry powder or a placebo. The placebo
consisted of cellulose and artificial food coloring, as well as sucrose, fructose,
magnesium hydroxide, and ascorbic acid in the same concentrations as in the
cranberry powder.

Improvements were seen in blood glucose levels, HbAic, fructosamine,
insulin, total cholesterol, triglycerides, and percent HDL for some subjects.
Glucose levels were significantly lower (p = 0.036) at week 12 in subjects who
had diabetes more than 5 years in the cranberry group compared to the
placebo group. At week 6, in subjects less than 50 years of age, blood
glucose levels decreased significantly (p = 0.030) in the cranberry group
compared to the placebo group. HbAlc levels decreased significantly (p =
0.031) in the cranberry group at week 6 in subjects who had diabetes more
than 5 years. Fructosamine levels improved significantly in patients less than
age of 50 in the cranberry group compared to the placebo group from week 0
to week 6 (p = 0.027). Triglyceride and total cholesterol levels were
significantly lower (p = 0.013 and p = 0.007 respectively) in the cranberry
group than the placebo group in subjects who had diabetes more than 5
years.

Cranberry supplementation may be beneficial for individuals with diabetes.
More research is needed in subjects with poor glycemic control and to
determine proper dosages.
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INTRODUCTION
BACKGROUND INFORMATION ON DIABETES MELLITUS
The Expert Committee on the Diagnosis and Classification of Diabetes
Mellitus (DM) defines diabetes as 'a

group of metabolic disorders

characterized by hyperglycemia resulting from defects in insulin secretion,
insulin action or bothn (1). Insulin is a hormone that is produced by the beta
cells of the pancreas and is necessary to utilize carbohydrate in the body.
Insulin increases oxidation, glycogenesis (production of glycogen), and
lipogenesis (production of fat from dietary carbohydrate), and helps to make
possible the diffusion of glucose into cells of the body (2). There are many
side effects associated with chronic hyperglycemia resulting from DM. The
side effects include cardiovascular disease, macrovascular and microvascular
disease, retinopathy, nephropathy, and neuropathy (1). Symptoms of DM
indude significant weight loss, polyphagia (excessive hunger), polydipsia
(excessive thirst), polyuria (excessive urination), and blurred vision (1, 2).

TYPES OF DIABETES MELLITUS
DM can be categorized as gestational DM, type 1 DM, type 2 DM, or other.
The focus of this research project was type 2 DM. In gestational DM glucose
intolerance occurs during pregnancy, and usually returns to normal after
childbirth. Up to 60% of women with gestational DM will develop type 2 DM
within 5 to 15 years (2).

Type 1 DM, or insulin dependent DM, usually occurs at an early age (less
than 30 years of age), however, the disease may occur at any age. In type 1
DM there is autoimmune destruction of the beta cells of the pancreas, which
halts insulin production. Glucose cannot be utilized without insulin, so glucose
is excreted in the urine. Patients with type 1 DM experience significant weight
loss, polyphagia, polydipsia, polyuria, and ketoacidosis (accumulation of
ketone bodies due to excessive breakdown of fat). Exogenous insulin is
necessary to prevent death in patients with type 1 DM (2).

Approximately 97% of people with diabetes have type 2 DM, previously
known as non-insulin dependent DM (3). Type 2 DM may occur at any age,
but occurs most often in individuals over the age of thirty. Endogenous insulin
secretion may be depressed, elevated, or normal, and there is a decrease in
insulin sensitivity in the body. With a decrease in insulin sensitivity, more
insulin is needed to control blood glucose levels in the body (2). The need for
more insulin results in higher than normal levels of insulin in the blood in
patients with type 2 DM. Type 2 DM has been linked to a sedentary lifestyle,
poor nutritional habits, and being overweight (4); however, people who
maintain a healthy weight may develop the disease. Individuals with type 2
DM may or may not experience excessive hunger, thirst, and urination, and
are unlikely to experience ketoacidosis (2). A patient may have type 2 DM for
many years without being diagnosed because blood glucose levels may be
elevated without causing symptoms severe enough to be noticed by the

patient (1). The preferred treatment for type 2 DM is lifestyle change, which
includes improved diet and exercise patterns. These changes are often
difficult for patients to maintain, so drug therapy may become necessary.

Oral medications that increase insulin secretion or improve insulin sensitivity
may be prescribed when diet and exercise changes are not successful. Oral
hypoglycemic

drugs

include

sulfonylureas,

meglitinides,

biguanides,

thiazolidinedione (TZDs), and alpha-glucosidase inhibitors. Sulfonylureas
increase insulin production by stimulating the pancreas. Chlorpropamide,
tolazamide, acetohedamide, and glipizide are examples of sulfonureas.
Repaglinide is a meglitinide, which increases insulin production by stimulating
the pancreas. Metformin (Glucophage) is a biguanide which increases insulin
sensitivity and decreases liver production of glucose. Rosiglitasone (Avandia)
and pioglitazone (Actose) are TZDs which improve insulin sensitivity and
improve carbohydrate metabolism. Precose and Glyset are alpha glucosidase
inhibitors which work by decreasing glucose absorption in the small intestine
(5). Type 2 DM may be treated with insulin in severe cases. Insulin therapy is

not usually necessary for survival, but is necessary to control blood glucose
levels and prevent side effects and complications of diabetes in approximately
40% of patients (2, 6).

DIAGNOSIS OF DIABETES MELLITUS
Screening for DM may be completed if a person has risk factors for the
disease, a family history of the disease, or shows symptoms of the disease. It
is recommended that all individuals over the age of 45 be tested for diabetes
every three years. According to the Expert Committee on Diagnosis and
Classification of DM, there are three criteria for diagnosis of DM. The first is
symptoms of diabetes with non-fasting plasma glucose greater than 200
mg/dL (11.lmmollL). The second criteria for diagnosing DM is a fasting
plasma glucose level greater than 126 mg/dL (7.0 mmoVL) (1, 6). This value
was changed in 1998 from 140 mgldL (7.8 mmol1L) to 126 mgIdL (7.0
mmol1L) in order to diagnose the disease earlier and prevent the many side
effects and complications of the disease (6, 7). The third criteria for diagnosis
of DM is a plasma glucose level greater than 200 mg1dL (11.1 mmol1L) two
hours after an oral glucose tolerance test (1, 6). Elevation of blood glucose
levels above 200 mg/dL (11.1 mmol1L) are associated with increased
incidence of diabetic complications (7).

COST OF DIABETES MELLITUS
In 1997 there were approximately 124 million people worldwide that had been
diagnosed with DM, and this number is increasing at an alarming rate (3). In
the period from 1990 to 1998 there was a 33% increase in the number of
Americans diagnosed with type 2 DM (4). With DM being diagnosed at 126
mgldL instead of 140 mg1dL starting in 1998, the increased incidence of DM
4

likely continued since 1998. The increased incidence of obesity in the United
States is a factor that likely contributed to the increased incidence of DM.
Type 2 DM is being diagnosed at much earlier ages. As early as 10 years ago
type 2 DM was a disease only found in adults, but at present as many as
300,000 children in the United States have the disease (4). It is important to

find a treatment to reduce the side effects of diabetes to decrease health care
costs and improve quality of life for patients with DM.

Persons with diabetes are three times more likely than nondiabetic persons
to be hospitalized, which leads to increased healthcare costs (3). Risk of
death is also higher in people with diabetes than non-diabetic persons (Table
1)-

Table 1: Relative Risk of Death for People with DM
Risk Of Death
Age 44 or younger
[ ~ g 45
e - 64
Age 65 or older

-

4.2 times higher

1 4.4 times higher

I

3 times higher
L

(3)

Patients with DM have higher healthcare costs. Both direct and indirect costs
are problematic. Direct costs include physician visits, hospital stays,
medications, etc. Indirect costs include sick days, loss of income, loss of
employment, and related expenses resulting from the disease (3). According

to the National Institute of Health, total cost of diabetes in 1997 was $98
billion. Direct medical costs were responsible for about $44 billion dollars and
indirect costs were about $54 billion dollars (6).

The American Diabetes Association evaluated the direct costs attributed to
DM in the United States in 1997 (8). Sixty-two percent of expenditure for care
of patients with DM was spent on inpatient care, 24.7% was spent on
outpatient services and home health care, 12.5% was spent on nursing home
care and 0.5% was spent on hospice care (Figure 1).

Figure 1: Healthcare Expenditures for Patients with DM
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Researchers also found that expenditures for health care in people with DM
increase as the patients age. Sixty-five percent of healthcare costs were for
patients 65 years of age or older. Indirect costs are also higher in individuals
with DM. Patients with DM lost an average of 8.3 days from work compared to
1.7 days for individuals without diabetes. Results of this study indicate that
health care costs are significantly higher for individuals with diabetes than for
those who do not have the disease.

Increased healthcare costs have been linked to increased glycosylated
hemoglobin (HbAlc) levels (3). Serum HbAlc is an indicator of blood glucose
control. A study by Gilmer et al. (9) investigated the cost of poor glycemic
control for a Health Maintenance Organization (HMO). The subjects recruited
for the study were all members of the HMO who had diabetes and were
continuously enrolled in the HMO for the 4 year period of the study.
Researchers found that when HbAlc levels were greater than 7%, healthcare
costs increased 10% for each percent increase in HbAlc. Results of the study
also indicated that in patients with heart disease and hypertension in addition
to diabetes, there was a significant decrease in health care cost associated
with a one percent decrease in HbA,c levels (Table 2).

INTENSIVE TREATMENT VS TREATMENT OF COMPLICATIONS

There are four major studies that have looked at the cost effectiveness of
better blood glucose control compared to treating the complications that occur

Table 2: Decreased Cost Associated with 1%Decrease in HbA,, Levels
Decrease In HbA,,

Cost Savings Per Year

as a result of years of hyperglycemia. These studies include the Diabetes
Control and Complications Trial (DCCT), Stockholm Study, the United
Kingdom Prospective Diabetes Study (UKPDS), and the Kumamuto Study.
Results of these studies suggest that intensive treatment of blood glucose
levels costs more than traditional treatments, but reduce complications of DM.
This leads to an overall cost reduction for DM patients with intensive
treatment (3, 10)

The DCCT (11, 12, 13) was a randomized clinical trial that compared the
effects of conventional therapy to intensive therapy in patients with type 1
diabetes. Fourteen hundred forty one subjects with type 1 diabetes were
followed for approximately 6.5 years. Participants were divided into two
groups; one group received conventional therapy and the other intensive
therapy. Subjects in the group receiving conventional therapy received one or
two insulin injections daily. Patients receiving intensive therapy received three

or more insulin injections daily to maintain blood glucose levels as close to
normal as possible. Results of the study indicated that subjects in the
intensive treatment group had significantly lower average HbAic levels than
the group receiving conventional treatment. This indicates that overall blood
glucose levels were significantly lower in the intensively treated group. There
was a 54% decreased risk of developing retinopathy with intensive treatment
than conventional treatment. Risk of developing microalbuminemia (protein
loss in the urine) decreased 34% with intensive treatment. At five years, the
risk of developing neuropathy was decreased by 69% with intensive treatment
when compared to conventional treatment. Results of this study indicated that
there is a decrease in side effects and complications of diabetes when blood
glucose levels are more tightly controlled (11, 12, 13).

In 1998, Turner published a review on the results of the UKPDS (14). The
main objective of the UKPDS was to determine if intensive control of blood
glucose levels in patients with DM would reduce risks for the side effects and
complications of DM. Five thousand one hundred two patients with type 2 DM
were recruited to participate in the study. Fifty percent of the subjects had
signs of tissue damage related to diabetes at the beginning of the study.
Initially all patients received diet therapy. The subjects were then randomized
into one of four treatment groups. One group was treated with conventional
therapy with dietary treatment, another group received intensive treatment
with chlorpramide, another group received intensive treatment with glyburide,

and the final group received intensive insulin therapy. An additional group of
obese individuals received metformin. In all intensive treatment groups the
goal of therapy was to achieve fasting glucose levels less than 108 mg/dL.
Results indicated that intensive treatment was successful in lowering blood
glucose concentrations, and that all methods of intensive therapy tested were
equally effective in controlling blood glucose levels. Intensive treatment of
diabetes can decrease blood glucose levels, which will decrease side effects
and complications of the disease (14, 15).

ACCOMPANYING CONDITIONS
There are many complications associated with development of DM including:
cardiovascular disease, stroke, neuropathy, nephropathy, and retinopathy
(16). The UKPDS has shown a reduction of microvascular complications
associated with DM, and a reduction of myocardial infarction with increased
control of blood glucose levels (16).

Cardiovascular Disease

Diabetes increases a patient's risk of developing heart disease. A man with
diabetes has double the risk of developing heart disease than a man without
the disease, and a woman with diabetes has four times greater risk of death
than a woman without the disease (4,7). The number one cause of death
among people with diabetes is cardiovascular disease (CVD). Diabetes is an

independent risk factor for CVD (4). Up to 80% of individuals with type 2 DM
will die from CVD (17).

The San Antonio Heart study, conducted by Wei et al. (18) was a 7 to 8 year
study investigating the effect of hyperglycemia on risk of developing CVD in
4,875 subjects. At baseline there were 471 subjects with diabetes and 4,404
non-diabetic subjects. An additional 27% of subjects developed diabetes
during the follow-up period. Researchers found that hyperglycemia is an
independent risk factor for CVD, and that risk for CVD increases as blood
glucose levels increase. It was also noted that TG levels increased and HDL
cholesterol decreased with increased plasma glucose levels.

Turner et al. (19) analyzed data from the UKPDS for risk factors for coronary
artery disease (CAD) related to diabetes. Results indicated that risk factors
for CAD were elevated levels of LDL cholesterol, triglycerides, HbAlc, fasting
plasma glucose, and systolic blood pressure, and low levels of HDL
cholesterol. There was a 1.57 fold increase in risk for CAD with each 1
mmoVL increase in LDL cholesterol and a 0.15-fold decrease in risk for CAD
with each 0.1 mmolIL increase in HDL cholesterol. This study also found an
11% increase in risk of CAD for each 1%increase in HbAlc.

Oxidation of LDL is a causative factor of atherosclerosis (20). It is believed
that antioxidants may have a protective effect and reduce the oxidation of

LDL. Flavonoids are antioxidants, and it has been shown that there is an
inverse relationship between intake of dietary flavonoids and coronary heart
disease (20, 21).

Neuropathy
Neuropathy is damage to the nervous system caused by chronic
hyperglycemia (22). Approximately 60 to 70% of people with diabetes have
some degree of neuropathy. Neuropathy may lead to impaired sensation in
the hands or feet, which can result in foot ulcers and amputation of
extremities. In the United States more than 50% of lower limb amputations
are the result of diabetes, with approximately 67,000 amputations being
performed yearly on people with diabetes. Autonomic neuropathy may lead to
gastrointestinal, genitourinary, cardiovascular or sexual dysfunction (1, 6, 23).
Symptoms of neuropathy include tingling or numbness in the extremities,
decreased ability to feel hot or cold, and impaired reflexes (23).

In a study published in 1997, Adler et al. (23) investigated risk factors for
diabetic peripheral sensory neuropathy. Subjects included 778 U.S. veterans,
of which 78% were white and 98% were male. Monofilament testing was used
to determine presence of neuropathy. Patients were tested at baseline and
were followed up within 2 to 3 years. Results indicated that height, age, HbAlc
level, and history of lower-extremity ulcer are all independent risk factors for
diabetic neuropathy.

Nephropathy
The primary cause of renal failure is DM. Approximately 10% of people with
renal failure has diabetes (24), and diabetes is responsible for approximately
40% of new cases of end-stage renal disease (6). Several factors may be
responsible for nephropathy in patients with DM. Oxidative stress may
damage the kidneys due to the increase in reactive oxygen species
associated with hyperglycemia and glycosylation of proteins (25). A high
concentration of aldose reductase in the inner medulla of the kidney leads to
the buildup of sorbitol, which can damage the kidneys (26). Many patients
with type 2 DM have high blood pressure, which increases stress on the
kidneys. Table 3 lists the stages in the progression of diabetic kidney disease.

Table 3: Stages of Nephropathy
P

I

Stage

Characteristics

Description

I

Hyperfiltration

Blood flow through kidneys increases

I

I

II

Microalbuminemia

111

Clinical Albuminemia

I

Small amounts of albumin lost in urine
Increased amounts of albumin and
other protein lost in the urine

IV

V

Advanced Clinical

Decreased glomerular filtration rate

Nephropathy

( ~ 7 muminute)
5

End Stage Kidney

Glomerular filtration rate c10

Disease

muminute

I

(27)

I

Retinopathy

Diabetic retinopathy is a side effect of both type 1 and type 2 DM, and risk of
developing diabetic retinopathy increases with duration of the disease (28)
Diabetic retinopathy is the leading cause of blindness in adults and is
responsible for 12,000 to 24,000 new cases of blindness each year (6). Early
characteristics of retinopathy include macroaneurisms (ballooning out of walls
of blood vessels), hemorrhages, and hard exudates (leakage of proteins and
lipids from the blood into retina). There are several mechanisms that lead to
diabetic retinopathy. The first is macular edema or fluid in the retina, which
results from buildup of hard exudates. The second is growth of new blood
vessels on the retina. The third is hemorrhaging from capillaries into the eye
(28).

Cataracts also lead to vision deficits in patients with DM. There is a high
concentration of aldose reductase in the lens of the eye; therefore, when
blood glucose levels are elevated, sorbitol accumulates in the lens. The high
concentration of sugar alcohol causes water to be pulled into the lens, which
leads to vision deficits. Inhibition of the enzyme aldose reductase may reduce
the vision impairments caused by DM.

LINK BETWEEN DIET AND DIABETES MELLITUS
The increase in incidence of type 2 DM is likely due to changes in dietary
habits. There have been numerous studies looking at the dietary habits of

patients with type 2 DM (29,30,31). A decline in consumption of whole grains,
fruits, and vegetables and an increase in consumption of highly processed
convenience foods and high fat fast food have been shown to increase risk
for developing type 2 DM.

Uusitupa et al. (32) investigated the effect of diet and exercise in preventing
or delaying onset of type 2 DM in patients with impaired glucose tolerance
(IGT) in the Finnish Diabetes Prevention Study. Five hundred twenty three
subjects with IGT were recruited for this ongoing controlled trial. The
treatment group was counseled to improve diet and exercise habits. The
advised diet contained greater than 50% of kcals from carbohydrates, less
than 30% from fat, less than 300 mg of cholesterol, and at least 15 grams of
fiber per day. After 1 year, subjects in the treatment group had significantly
lower 2 hour glucose levels, fasting glucose levels, and 2 hour insulin levels
than the control group. Results of this study suggest that there is a decreased
risk of developing type 2 DM with changes in diet and exercise habits.

Ford and Mokdad (33) investigated whether consumption of fruits and
vegetables had a preventive effect for DM. Researchers followed 9,665
subjects for approximately 20 years, and mean daily intake of fruits and
vegetables was recorded. Results indicated that the mean number of fruits
and vegetables eaten daily was lower in the group that developed DM. There

was also a lower percentage of people who consumed 5 or more servings of
fruits and vegetables daily in the group that developed DM.

A study published in 2002 by van Dam et al. (29) looked at the association
between dietary intake and risk for developing type 2 DM. This study was a
prospective cohort study in which 42,504 professional men were followed for
12 years (1986 to 1998). A food frequency questionnaire was given every 4
years and was used to determine foods commonly eaten by subjects, portion
sizes consumed, and how often specific foods were consumed. Every 2 years
participants were given a questionnaire about "exposures and newly
diagnosed diseases." Subjects were grouped into one of two dietary patterns,
either prudent or western. The prudent dietary pattern was characterized by a
high consumption of whole grains, fruits, vegetables, and fish. The western
dietary pattern was characterized by a high consumption of red meat,
processed meat, French fries, high fat dairy products, sweets and desserts,
and refined grains. Results of this study indicated that the risk of developing
type 2 DM increased in participants with the western dietary pattern, and
decreased with consumption of the prudent dietary pattern.

A study conducted by Ekblond et al. (31) looked at the effects of dietary
intake on urinary glucose excretion, which is a predictor of type 2 DM. The
cross-sectional study took place between December 1993 and April 1997,
and 27,146 Danish men and 29,861 women participated in the study. All

participants filled out a food frequency questionnaire and a lifestyle
questionnaire with questions about smoking, alcohol intake, physical activity
and medical history. Subjects who experienced urinary glucose excretion
during the study were compared to subjects who did not. Investigators found
that persons with glucosuria tended to eat more meat and less fruits and
vegetables, cereal grains, and poultry than subjects who did not experience
glucosuria.

Control of blood glucose levels can be monitored by measuring blood glucose
concentrations, fructosamine levels or glycosylated (glycated) hemoglobin
(HbAlc) levels. Measurement of serum glucose levels is an indication of
current blood glucose control (1). The fructosamine assay measures
glycosylated albumin or glycosylated total proteins. According to Arrnbruster
(34), fructosamine is a "ketoamine" which is produced by a non-enzymatic
reaction between a sugar and a protein. The sugar is normally glucose and
the protein normally albumin. Measurement of fructosamine levels is an
indicator of blood glucose control in the 2 to 3 weeks prior to the test (34).
Glycosylated hemoglobin is a hemoglobin protein that a glucose molecule has
covalently attached itself to. These proteins are more susceptible to oxidative
damage than normal hemoglobin molecules. Serum HbAlc levels are an
indication of blood glucose control in the previous 3 months. Because the life
span of a red blood cell is 3 months, it takes this long for all of the hemoglobin

molecules in the body to turnover. HbAlc and fasting glucose tests are the
methods that are currently recommended to monitor treatment of diabetes by
the Expert Committee on the Diagnosis and Classification of Diabetes
Mellitus (1). Treatment goals for individuals with type 2 DM are listed in Table
4.

Table 4: Methods of Monitoring Treatment of DM
Presence Of Hyperglycemia

Normal Values

Blood glucose levels

Immediate

3.9 to 7.0 mmoVL

Serum Fructosamine

Previous 2 to 3 weeks

1.6-2.6 mmolIL

Previous 3 months

Less than 6%

Indicator

Serum HbA,,

(1, 35)

PROTEIN GLYCOSYLATION
Protein glycosylation (or glycation) is a direct non-enzymatic reaction between
a reducing sugar and the amino group of a protein (36). This is a nonenzymatic reaction where the glucose molecule covalently attaches itself to a
reactive amino group. The rate at which this reaction occurs is dependent on
blood glucose concentrations. These glycated proteins are precursors to
advanced glycation products. Non-enzymatic glycation of proteins is also
damaging to the body because this increases the rate of free radical
production 50-fold (37).

Many proteins in the body experience glycosylation when blood glucose
levels are elevated. Proteins susceptible to protein glycosylation include
hemoglobin, red blood cell membrane proteins, albumin, collagen, myelin,
and proteins in the lens of the eye. Protein glycosylation is an oxidation
reaction; therefore, it is believed that antioxidants are effective in preventing
this reaction (36).

ALDOSE REDUCTASE
Aldose reductase is known to be the cause of many of the complications of
type 2 DM including cataracts, retinopathy, nephropathy, and neuropathy.
Aldose reductase is an enzyme found in the body that is responsible for the
reduction of glucose to sorbitol in the polyol pathway (Figure 2) (37). This
reaction occurs when D-glucose is converted to sorbitol by aldose reductase.
This pathway is only active when blood glucose concentrations are elevated
(38). Hexokinase is an enzyme that converts glucose to glucose-&phosphate.
Glucose-6-phosphate is the form of glucose that is used by the cells of the
body. When hexokinase becomes saturated due to hyperglycemic conditions,
aldose reductase is activated to convert excess glucose to sorbitol. Sorbitol
cannot be used in the body as a fuel source, so it needs to be converted to
something useable. The enzyme sorbitol dehydrogenase converts sorbitol to
fructose; however, concentrations of sorbitol dehydrogenase do not increase
in proportion to concentrations of sorbitol, so sorbitol builds up in the tissues.
The fructose that is converted from sorbitol may also damage proteins due to

enzymatic fructosylation of proteins. The fructose may be converted to 3deoxyglucosone, which is a precursor to advanced glycation end products.
This pathway also leads to production of free radicals for autoxidation of
glucose, hydrogen peroxide (H202),and superoxide molecules (02.) (37).

Figure 2: Polyol Pathway
Normal Glucose Metabolism:
Glucose

ucose-SPhosphate

Hexokinase

With Hyperglycemia

(37)
If an increase in aldose reductase is responsible for many of the side effects
of diabetes, including neuropathy, nephropathy, and retinopathy, then finding
a way to inhibit this enzyme may decrease the side effects of DM and
improve quality of life for people with DM (36).

In a study published in 2002, Obrisiva et al. (39) investigated the effect of
sorbinil, an aldose reductase inhibitor, on rat peripheral nerve function,
metabolism and antioxidant defense. When a dose of 65 mglkg of body
weight of sorbinil was given, there were significant improvements in
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neurovascular function and nerve conduction. An improvement in metabolic
abnormalities was also noted. Lipid peroxidation was increased in diabetic
rats compared to the control group, but the lipid peroxidation was arrested
with administration of sorbinil.

Hamada et al. (40) investigated the effect of epalrestat, a known aldose
reductase inhibitor, on the accumulation of end products of glycation. Blood
was drawn from 38 subjects with type 2 DM. Sixteen of the subjects had been
taking 150 mg of epalrestat daily for 2 months and 38 had not been treated
with the drug. Sorbitol, fructose, triglycerides, carboxymethyl-lysine (CML),
triosephosphates,

erythrocyte

3-deoxyglucosone

(3-DG),

and

the

thiobarbituric acid-reactive substance (TBARS) assay were measured.
TBARS are products of the decomposition of hydroperoxides. Sorbitol and
fructose are products of the polyol pathway, and CML, triosephosphates, 3DG are advanced glycation end products. Results indicated that sorbitol,
fructose, triosephosphates, TBARS and 3-DG levels were significantly lower
in subjects receiving epalrestat than in patients not receiving the drug. There
were no changes in plasma glucose or HbAlc levels. These results suggest
that inhibition of the enzyme aldose reductase can reduce the end products of
protein glycosylation.

A study conducted by Vincent et al. (38) investigated the ability of vitamin C to
inhibit aldose reductase. Human erythrocytes collected from normal

volunteers were used for the study. The erythrocytes were incubated with
increasing concentrations of glucose from 5 to 40 mM, and sorbitol
concentrations increased progressively with the increasing concentrations of
glucose. Ascorbic acid was then added and was found to decrease
intracellular sorbitol concentrations by 25 to 45 %.

Pfeifer et al. (22) conducted a review of research completed investigating the
efficacy of aldose reductase inhibitors (ARI) on the side effects of diabetes. Of
32 clinical trials on the effect of ARI on distal symmetrical polyneuropathy,
59% showed positive results on at least one measure. Most often motor nerve
conduction velocity was improved by treatment with an ARI. Of 15 trials
conducted on the effect of ARI on autonomic neuropathy, 5 showed
improvement in autonomic neuropathy. These trials indicate that ARI may be
a promising treatment to reduce side effects in patients with DM, but due to
the number of studies that have not shown positive results, more research
needs to be completed.

ALTERNATIVE TREATMENTS
Use of complementary and alternative medicine (CAM) has become popular
recently for treatment and prevention of disease. CAM is defined as use of
therapies and treatments that are not used in conventional medicine (41).
Several research studies have investigated the used of CAM in treatment of
diabetes.

Egede et al. (41) analyzed data collected in the Medical Expenditure Panel
Survey (MEPS) conducted in 1996. The MEPS collected data on CAM use,
medical conditions, health insurance, demographic information, and health
care expenditures for US citizens. Egede et al. analyzed data on
demographics, medical conditions and CAM use. Results of the survey
indicated that patients with DM were more likely to use CAM than patients
with no chronic diseases. The CAM therapies most often used by patients
with DM were nutritional advice, spiritual healing, herbal remedies, massage
therapy, and meditation training.

Ryan et al. (42) conducted a survey investigating the use of CAM in patients
with diabetes. Five hundred two patients with diabetes and 201 nondiabetic
control subjects were surveyed. Results indicated that 78% of patients with
DM were taking prescription medications compared to 63% of non-DM
patients. When use of over-the counter supplements (OTCS) were compared,
researchers found that 44% of patients with DM compared to 51% of non-DM
patients were taking OTCS. Thirty-one percent of patients with DM were
using CAM compared to 37% of non-DM subjects. CAM supplements used by
subjects with DM included garlic, Echinacea, glucosamine, chromium, ginkgo
biloba, cayenne and St. John's Wort. Only patients with DM reported taking
chromium, which is believed to improve blood glucose control. Researchers
also found that patients with DM spent approximately the same amount on
over-the-counter supplements and alternative medicine as they did on

prescription medications ($23.53 per month for OTC and CAM supplements
compared to $28.51 for prescription medications). Subjects with DM used
CAM supplements and OTCS in addition to prescription medications, rather
than replace prescription medications with CAM supplements and OTCS.

ANTHOCYANINS AND FLAVONOIDS
Anthocyanins and flavonoids are chemicals found in fruits, vegetables, nuts,
seeds, stems, flowers, tea, and wine that are powerful antioxidants. These
compounds have been shown to improve resistance of LDL to oxidation,
protect against oxidative damage, decrease protein glycosylation and affect
enzyme activity (36). Fresh berries are a rich source of flavonoids and
anthocyanins. Lipid oxidation is believed to be a causative factor in
cardiovascular disease. Antioxidants, such as anthocyanins and flavonoids
found in fruits and vegetables, can help protect against lipid oxidation and
therefore protect against cardiovascular disease.

Protein Glycosylation
Camire et ai. (43) investigated the ability of fruit anthocyanins to inhibit aldose
reductase in-vitro. Fruit powders of raspberries, blueberries, cranberries and
grapes were analyzed as well as the flavonoid quercetin and anthyocyanin
aglycones cyanidin, delphinidin and malvidin. Aldose reductase was inhibited
10 to 52% by fruit powders. Raspberries were most effective at inhibiting
aldose reductase followed by blueberry and cranberry powders. Grape
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powder was the least effective inhibitor of aldose reductase. Over 90% of the
aldose reductase was inhibited by quercetin, cyanidin and delphinidin, and
only 70% was inhibited by malvidin.

Keenoy and De Leeuw (44) investigated the effect of Daflon, a flavonoid
preparation containing 90% diosmin and 10% hesperidin, on protein
glyosylation and antioxidant status. Twenty-eight subjects with type 1 DM
participated in the 3-month double-blind, placebo-controlled study. Blood
glucose and HbAic levels were measured to determine blood glucose control
and protein glycosylation. Antioxidant capacity was measured by determining
reduced glutathione (GSH) and gluthione peroxidase content in red blood
cells. Blood glucose levels remained constant during the course of the study,
but HbAlc levels decreased significantly with flavonoid treatment. No
significant differences in antioxidant activity were found between the flavonoid
group and the placebo group.

Asgary et al. (36) conducted a study which looked at the effect of the
flavonoids quercetin, rutin, and kaempherol on protein glycosylation in vitro.
The optimal concentration and incubation time of flavonoids to reduce protein
glycosylation was investigated. A colorimetric method was used to determine
the degree of hemoglobin glycosylation in the presence of each flavonoid.
Results of the study indicated that all three of the flavonoids had a preventive
effect on protein glycosylation (Table 5). The preventive effect of the

flavonoids on protein glycosylation was dependent on the concentration of the
flavonoid. Quercetin had the greatest effect on protein glycosylation and
kaempherol had the least effect. Additional studies need to be completed to
determine whether flavonoids have the same effect on protein glycosylation in
vivo (36).

Table 5: Inhibition of Hemoglobin Glycosylation by Flavonoids
P

Flavonoid

Rutin
Quercetin

0.5 pg/mL

5 pg/mL

10 pg/mL

11%

27%

42%

37%

52%

(36)

In 2000, a study by Jankowiski et al. (45) investigated the effects of
anthocyanin pigments from red wine on diabetes. The study used 80 rats
divided into 4 groups: a control group, a group receiving streptozotocin to
induce diabetes, a group receiving intragastric anthocyanins, and a group
receiving streptozotocin and anthocyanins. Glucose concentrations in blood
and urine increased in the rats after streptozotocin was injected, but was
decreased in the animals receiving anthocyanins. There was a substantial
decrease in blood and urine glucose, a reduction in free radical production
and a decrease in the concentration of products of unsaturated fatty acid

oxidation in blood and urine in the group of rats receiving streptozotocin and
anthocyanins.

Lipid Oxidation
In 1997 Laplaud et al. (20) conducted a study looking at the antioxidant effect
of blueberry extract on human LDL in vitro. Plasma was obtained from 6
fasting adult Caucasians, and the LDL was isolated by ultracentrifugation.
Copper chloride was used to induce LDL oxidation. A lipoperoxide assay, a
TBARS assay, and relative electrophoretic mobility (REM) were performed on
the LDL to determine the amount of oxidation with the addition of differing
amounts of blueberry extract. The results indicated that the blueberry
antioxidants are effective in inhibiting the oxidation of LDL at concentrations
as low as 15 pg1mL.

In 1998, Heinonen et al. (46) conducted a study looking at the effect of
polyphenolics found in berries on oxidation of LDL and liposomes. The berries
chosen for this study included blackberries, red raspberries, sweet cherries,
blueberries, and strawberries. In this study LDL oxidation was completely
inhibited by all berries except strawberries and blueberries. Berry extracts
were successful in inhibiting 27 to 68% of hydroperoxide formation and 60.5
to 92.6% of hexanal formation.

In 1999, Gabrielska et al. (47) conducted a study looking at the effect of
anthocyanin pigments extracted from chokeberry, honeysuckle and sloe on
lipid oxidation in vitro. Lipid oxidation was induced in the liposome membrane
by ultraviolet radiation. The amount of oxidation was evaluated by a TBARS
assay. HPLC was used to evaluate the end products of lipid membrane
oxidation. The results of this study indicated that the anthocyanins found in
chokeberry, honeysuckle and sloe are protective against free radical oxidation
of the lipid membrane.

Many research studies have been completed investigating the effect
anthocyanins and flavonoids have on DM. The results indicate that these
compounds have a protective effect on lipid oxidation and protein
glycosylation in vitro. More research needs to be completed to determine if
the same effects occur in vivo.

CRANBERRIES
Cranberries (Vaccinium macrocarpon) have been believed to be useful to
prevent disease and treat illness for hundreds of years. Native Americans
used cranberries to treat wounds and blood poisoning, and American sailors
ate cranberries to prevent scurvy. The leaves of the cranberry plant have
been used to treat diarrhea, urinary disorders and diabetes. Most research
has been focused on the ability of cranberry juice to prevent and treat urinary
tract infections (48). Cranberries are widely used as a treatment for urinary

tract infections, even though conclusive documentation has not been
published.

Composition
In a study published in 2001, Prior et al. (49) analyzed the anthocyanin
content of blueberries and cranberries. Researchers found that the four major
anthocyanins that are responsible for the red color of cranberries are
cyanidin-3-galactoside, peonidin-3-galactwide, cyanidin-3-arabinoside, and
peonidin-3-arabinoside. Cranberries also contain smaller amounts of the
anthocyanin cyanidin-3-glucoside and peonidin-3-glucoside (Table 6).

Table 6: Percent of Anthocyanins found in Cranberries
~nthoc~anins

I % Of Total Anthocyanins

I

Peonidin-3-arabinoside

15.8

In an article published in 2001, Kahkonen et al. (50) reported the phenolic and
anthocyanin content of berries and apples. Cranberry ( Vaccinium oxycoccus)
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samples were extracted by acetone extraction and then dried and frozen for
up to 1 week before being analyzed. The cranberries contained 397 mg of
anthocyanins per 1009 of dry weight of cranberries. The flavonoid content of
the analyzed sample was 200 mgl100g dry weight.

Hakkinen et al. (51) investigated the content of the flavonoids quercetin,
myricetin and kaemphferol in berries including cranberries. Vaccinium
oxycoccos, a species of wild cranberry, was used in this study. Researchers
found large amounts of quercetin (83 to 121 mglkg) and myricetin (74 to 142
mglkg) in the cranberry samples, but kaemphferol was not found. Cranberry
had the second highest total flavonoid content (157 to 263 mglkg) of the
bemes analyzed, second only to bog whortleberry (184 mglkg).

Bioactivity of Cranberry Components
Pedersen et al. (52) conducted a study comparing the antioxidant capacity of
cranberry and blueberry juice in the plasma of nine female volunteers.
Researchers used ferric reducing antioxidant value (FRAP value) as one
measure of plasma antioxidant activity, and electron spin resonance
spectroscopy (ESR) to determine the ability of the plasma to donate a
hydrogen atom or electron to a free radical. Results indicated that
consumption of blueberry juice did not significantly increase concentrations of
total phenols or vitamin C in the plasma of the volunteers. Researchers
question how readily the phenols are absorbed in the gut. Consumption of

cranberry juice did lead to significant increases in total phenols and a 30%
increase in serum vitamin C concentration. Researchers question if the
increase of total phenols in serum following cranberry juice consumption is
primarily due to the increased vitamin C levels.

Wilson et al. (53) conducted a study looking at the ability of cranberry extract
to protect against low density lipoprotein oxidation. LDL was separated from
the serum of 5 male volunteers and used for the study. Oxidation of the LDL
samples was promoted and cranberry extract was added to each sample at
concentrations of 0.00%, 0.10%, 0.010%, or 0.005%. After incubation, the
samples were tested for oxidation by TBARS and electrophoresis. Results
indicated that TBARS were inhibited at a 0.10% dilution and electrophoretic
movement was reduced significantly when up to 0.05% dilution of cranberry
extract was used. In this study cranberry inhibited LDL oxidation in-vitro.

Wang and Jiao (54) investigated the protective effect of cranberries,
blackberries, blueberries, raspberries, and strawberries against superoxide
radicals (0;-),

hydrogen peroxide (H202), hydroxyl radicals (OH), and singlet

oxygen (02). Researchers found that the ability to inhibit oxidation by these
radicals varied by cultivars, but all cranberries tested inhibited greater than
54% of 0;-,

greater than 55% of H202, greater than 59% of OH, and greater

than 7% of 02.

There has been a great deal of research investigating the effects of cranberry
anthocyanins and flavonoids in vitro. It is possible that cranberry
supplementation may decrease the protein glycosylation and lipid oxidation
that contribute to the side effects of DM. The anthocyanins and flavonoids in
cranbeny may inhibit the enzyme aldose reductase, and therefore may inhibit
the buildup of sorbitol in tissues of the body.

MATERIALS AND METHODS
STUDY DESIGN

Twenty-seven adults with type 2 DM, controlling their disease with diet and
exercise, were recruited for this twelve week, double blind, placebo controlled
study. Subjects were recruited from ads placed in the Bangor Daily News and
in the Maine Perspective. Fliers were put up at local stores and health clubs,
and notices were posted on the First Class University of Maine computer
conference. Patients taking oral medications or insulin to control blood
glucose levels were not invited to participate in the study. The University of
Maine Protection of Human Subjects Review Board approved the study.
Subjects were randomly assigned to either the cranberry group or the placebo
group. Participants were asked to fill out an informed consent form (Appendix
A), a health history questionnaire (Appendix B), and a food frequency
questionnaire (Appendix C) at the first blood draw. Instructions were provided
on the front page of the questionnaires, and someone was available to
answer questions while subjects were filling out the questionnaires. During
the study, participants were asked to take 6 capsules daily filled with either
the cranberry powder or the placebo, and have blood drawn at 0, 6, and 12
weeks (Figure 3). Blood samples were taken after an overnight fast. A stipend
of $50 dollars was given to each subject after each of the three blood draws
for a total of $150.

Figure 3: Study Design
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CRANBERRY TREATMENT
Size

00

gelatin

capsules

(00-coni-shape)

(Feton

Chemical

and

Pharmaceutical Company, Ramsey, NJ) were filled with Decas Cranberry
Juice Concentrate Powder 90 (product code 06054), which was generously
provided by Decas Cranberry Products (Wareham, MA). A Feton model 101
capsule filling machine was purchased from Feton Chemical and
Pharmaceutical Company (Ramsey, NJ).

The capsules were opened by the filling machine, and were then filled with
the powder. The powder was tamped down three times to ensure that the
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capsules were filled completely. The machine then closed the capsules. Ten
empty capsules were weighed with a Sartorius Analytical balance (model
A2005, Sartorius Corporation, Edgewood, NY), and the total was divided by
10 to get the average weight of one capsule. The weight of an empty capsule
was 0.12 grams. The average weight of the filled capsules was 0.64 grams.
Each capsule of cranberry powder contained approximately 0.53 grams of
Decas Cranberry Juice Concentrate Powder 90. The cranberry powder is
90% cranberry juice, so the weight of actual cranberry juice in each capsule is
0.48 grams.

The subjects in the treatment group were given cranberry capsules that
contained the equivalent of eight ounces (240 mL) of cranberry juice cocktail,
since that beverage is the major form of cranberry consumed in the United
States. To calculate the amount of cranberry powder each subject needed
daily, it was first important to know that liquid commercial cranberry juice
cocktail contains approximately 27% cranberry juice. The Decas Cranberry
Juice Concentrate Powder 90 is 90% cranberry juice. Nutrition information
from Nutritionist 5 Nutrient Database (First DataBank, San Bruno, CA) was
used to calculate the amount of cranberry in commercial juice. Each 8 ounce
serving of cranberry juice cocktail weighs 253 grams. There are 216 grams of
water and 34.2 grams of sugar in each 253-gram serving of juice. The water
and sugar in the juice were subtracted from the total weight; 2.8 grams of
cranberry juice are present in each 8 ounce serving of cranberry juice. The

cranberry powder is 90% cranberry juice, so the weight of cranberry powder
in each capsule (0.53 grams) was multiplied by 90% to get the amount of
cranberry juice in each capsule (0.48 grams). With 0.48 grams of actual
cranberry juice in each capsule, six (5.89) cranberry capsules were required
to equal an eight ounce serving of cranberry juice. Table 7 displays the
nutritional information for cranberry powder.

Table 7: Nutritional Analysis of Cranberry Powder'
P

Nutrient

Amount per 3 gram Sewing

Calories

10.8 kcals

Carbohydrate

2.7 g

Sugars

1.2 g

Potassium

27.3 mg

Calcium

2.1 mg

Magnesium
L

183.4 mg
I

I

Nutrition information provided by Decas Cranbeny Products Wareham, MA.

SUGAR ANALYSIS OF CRANBERRY POWDER
High performance liquid chromatography (HPLC) analysis was performed on
the Cranberry Juice Concentrate Powder 90 using a Hewlett Packard HP
3394 Integrator (Palo Alto,

CA), a Waters Associates Differential

Refractometer, model R401 (Milford, MA), a Shimadzu LCO6A isocratic pump
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(Braintree, MA), a Primesphere NH2, 5p, 250 x 4.6 mm HPLC column
(Phenomenex Inc. Torance, CA), and a VlCl model E 60 injector (Valco
Instruments Co Inc. Houston, TX). Acetonitrile (HPLC grade, A998-4) and
water (HPLC grade, W5-4) for the HPLC analysis were purchased from EM
science (Gibbstown, NJ). SIGMA ultra fructose (F2543) and sucrose (51174)
were purchased from SIGMA Chemical Company (St Louis, MO). Anhydrous
dextrose (D16-500) was purchased from TT Baker Chemical Company
(Phillipsburg NJ).

High-performance liquid chromatography was used to determine the
percentage of glucose and fructose in the Decas Cranberry Juice
Concentrate Powder 90. This information was necessary to ensure that the
placebo contained the same concentrations of glucose and fructose as the
treatment. The mobile phase was 75% acetonitrile and 25% water, and a flow
rate of 1.5 mL per minute was used. Five grams of Decas Cranberry Juice
Concentrate Powder 90 was mixed with enough ethyl alcohol (ETOH) to
make a 50 mL solution. The standard was mixed using 0.0786 grams of
fructose, 0.0782 grams of dextrose, 0.0743 grams of sucrose and enough
85% ETOH to bring the solution up to 100 mL. Twenty-five pL of standards
and sample solutions were injected into the HPLC system. The
chromatogram of HPLC sugar analysis of cranberry powder is located in
Appendix D.

The following equation was used to calculate the amount of each sugar per
mg of cranberry powder:

Glucose =
or fructose

(peak heiaht-sample (cml \ x (conc of std mg1mL) x ( 5 0 m ~(total volume of sarnplel\
peak height-std (cm) 1
\ 0.5 grams (sample wt)
1

\

conc = concentration

std = standard

wt = weight

The average of two analyses was used to determine the percentage of
glucose and fructose in the Cranberry Juice Concentrate Powder 90.

PLACEBO
To ensure that any results were an effect of the cranberry powder and not the
concentration of sugar, magnesium or ascorbic acid, it was important to
ensure that the placebo contained the same concentrations of glucose,
fructose, magnesium hydroxide, and ascorbic acid as the cranberry
treatment. HPLC analysis of the Decas Cranberry Juice Concentrate Powder
90 indicated that each gram of the powder contained 57.6 mg (6%) of
fructose and 184.2 (18%) mg of glucose. The Decas Cranberry Juice
Concentrate Powder 90 is processed using magnesium hydroxide. Each
gram of the cranberry powder contains 61.13 mg (6%) of magnesium. The
Decas Cranberry Juice Concentrate Powder 90 contains 1 mg of ascorbic
acid per gram of powder, which makes it 0.1% ascorbic acid.

A total of 4000 grams of the placebo powder was made. Purified cellulose
(grade: just fiber, BH 65FCC, International Filler, North Tonawanda, NY) was
used as the base of the placebo. The composition of the placebo is listed in
Table 8. Magnesium hydroxide powder (USP Grade) was generously
provided by Watson Foods Co. Inc. (West Haven, Ct). Dextrose corn sugar
(020010-102, Corn Products International, Bedford Park, IL), fructose (95603, ADM Corn Processing, Decatur, IL), and Now fine ascorbic acid powder
(0792, Now Foods, Glendale Heights, IL) were purchased from Natural Living
Center (Bangor, ME). Red (E1248) and violet (E0680) food coloring were
purchased from Lorann Oils (Ramsey, NJ). Placebo capsules were filled
using the same methods as the cranberry capsules and were approximately
the same weight as the cranberry capsules.

Table 8: Composition of Placebo Powder
Component

Amount (Grams)

Amount (%)

Cellulose

2396

59.9

Glucose

729

18

Magnesium Hydroxide

240

6

Red Food Coloring

200

5

200

5

4

0.1

I

I

Violet Food Coloring
Ascorbic Acid
*

BLOOD ANALYSIS
All blood draws were done at the phlebotomy laboratory at Cutler Health
Center at the University of Maine, Orono, by Sally Hall, American Society of
Clinical Pathology (ASCP) Medical Technologist, Amy Kelly, ASCP Medical
Technologist, and Andy Phellen, ASCP Medical Technologist. The tubes of
blood were allowed to settle for half an hour before being centrifuged. For
each patient, one tube of blood was sent to Affiliated Laboratory, Bangor,
Maine and one tube was taken to Dr Camire's laboratory in Holmes Hall,
University of Maine. Total cholesterol, triglycerides, LDL, HDL, percent HDL,
fasting glucose, and HbAlc, levels were analyzed by Affiliated Laboratory,
insulin levels were analyzed at Associated Regional and University
Pathologists Inc. (ARUP), and fructosamine levels, aldose reductase activity,
and hexanal concentration were analyzed by myself at the Holmes Hall
laboratory. Single values per subject per blood draw were reported by
Affiliated Laboratory.

Fasting Blood Glucose
Fasting blood glucose is a measure of how well the patient's blood glucose
levels are being controlled at the present time. This analysis is accepted by
the American Diabetes Association as a standard method to diagnose and to
monitor treatment of DM. A decrease in blood glucose levels from baseline to
week 12 for patients in the treatment group would indicate that cranberry
supplementation had an effect on blood glucose levels. Analysis of fasting
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glucose was done at Affiliated Laboratory in Bangor, Maine using the oxygen
electrode method and a Beckman Coulter LX20 Pro clinical system (Fullerton,
CA).

Glycosylated Hemoglobin

Glycosylated hemoglobin is a useful measure of the effectiveness of
treatment to control blood glucose levels in the previous 3 months (36). A
value less than 6% is considered normal. The treatment goal for a person
with diabetes is to have an HbAlc level less than 7% (1). Levels over 7% have
been shown to increase incidence of side effects and complications of
diabetes. This analysis was chosen because a change in HbAlc levels
between baseline and week 12 in the treatment group would indicate a
decrease in protein glycosylation with cranberry supplementation. Blood
analysis of HbAlc levels was completed at Affiliated Laboratory in Bangor,
Maine using the BioRad Variant II HPLC method.

Serum Insulin
Insulin is a hormone necessary for the utilization of carbohydrate. As insulin
sensitivity decreases in patients with type 2 DM, the body produces more
insulin in an attempt to control elevated blood glucose levels (2). Some oral
medications used to treat diabetes increase pancreatic insulin secretion.
Normal blood insulin levels are 5-35 mmol/L (30

- 210

pmol/L). Blood

analysis of insulin levels were completed at ARUP (Salt Lake City, Utah)
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using a chemiluminescent immunoassay. ARUP provided interpretive data
with the results.

Cholesterol and Triglyceride Levels
Diabetes is an independent risk factor for CAD. Elevated total cholesterol,
LDL cholesterol, and triglyceride levels as well as low levels of HDL
cholesterol are additional risk factors for coronary artery disease. Patients
with diabetes have higher total cholesterol, LDL cholesterol, and triglyceride
levels and lower HDL levels that the general population (19). Due to the
relationship between diabetes and CAD it is important to control cholesterol
and triglyceride levels in patients with diabetes. It is especially important to
control levels of LDL cholesterol because LDL can become glycated with
elevated blood glucose levels, and these glycated LDL molecules are easily
oxidized (19). Table 9 shows the 2001 National Heart, Lung and Blood
Institute recommendations for optimal cholesterol levels.

Table 9: Recommendations for Cholesterol Levels

A

Cholesterol

Recommendation (mgldL)

Recommendation (mmol/L)

Triglycerides

< 150

1.7

Total Cholesterol

~200

5.2

LDL

400

2.6

HDL

40 to 60

1.0 to 1.6

Serum levels of total cholesterol, triglycerides and HDL were analyzed at
Affiliated Laboratory utilizing a Beckman Coulter LX20 Pro clinical system and
time endpoint methodologies. LDL and percent HDL were calculated using
the results of the total cholesterol and HDL cholesterol (55). The equation
used to calculate LDL is:

-

-

LDL (mg1dL) = total cholesterol HDL cholesterol TG 15

Percent HDL is calculated by the following equation:

Percent HDL = HDL Itotal cholesterol * 100

When total cholesterol level was greater than 200 mg/dL (5.2 mmolIL), direct
LDL was analyzed using the Beckman Coulter W 0 Pro clinical system and a
liquid selective detergent method.

Fructosamine levels are a measure of glycosylated albumin, and are an
indicator of blood glucose control in the 2 to 3 weeks prior to the test (34).
Normal values for fructosamine in patients who do not have diabetes are 1.6
to 2.6 mmol1L. The normal range for patients with diabetes is 2.1 to 5.0
mmoUL (35)

Fructosamine Kits (Procedure No.465) were purchased from Sigma
Diagnostics (St. Louis, MO). A Spectronic 20D+ spectrometer from Spectronic
Instruments (Rochester, NY) and a heat block (Fisher Scientific Company,
Fair Lawn, NJ) were used to perform the analysis. Fisher brand micro
cuvettes (14-385-938) were purchased from Fisher Scientific Company (Fair
Lawn, NJ).

The SIGMA Fructosamine Kit (Procedure No.465) was used for analysis of
serum fructosamine levels. To complete the analysis, the fructosamine
reagent solution was first heated to 37°C. The spectrophotometer was set to
a wavelength of 530 nm and the absorbance was zeroed using deionized
water as a reference. The concentration of the fructosamine calibrator
solution was recorded from the label on the bottle. Micro-cuvettes were
numbered allowing for 1 cuvette for the calibrator and enough cuvettes to
analyze each sample in duplicate. For the calibrator, 1.0 mL of reagent and
0.1 mL of fructosamine calibrator solution was pipetted into cuvette number 1.
For each sample, 1.0 mL of reagent solution and 0.1 mL of the appropriate
serum sample was pipetted into each of the other cuvettes. Each cuvette was
then mixed by covering with para film and inverting gently. All cuvettes were
incubated at 37°C for 10 minutes. After exactly 10 minutes the absorbance of
each cuvette was recorded as initial A. Tube number 1 was recorded as Initial
~ .
A ~ and
, each of the other cuvettes was recorded as Initial A ~All~cuvettes

were then incubated for exactly 5 more minutes (for a total of 15 minutes) and

the absorbance of each cuvette was recorded as Final A. Cuvette number 1
was recorded as Final ACa',and the each of the other cuvettes was recorded
as Final AteS'.The following calculation was performed for each sample (35):

Frudosamine (mMoVL) = Final AteS'- Initial AkSt

-

Final Am' Initial ACa'

x Concentration
of
Calibrator

Aldose Reductase Activity
Sample Preparation
The method used to analyze aldose reductase activity was derived based on
a method by Renner et al (56). To perform the deproteinization of the
samples 100pL of serum, 100pL of 0.69 mM dulcitol (DO-0256 SIGMA
Chemical Company, St. Louis, MO), and 1mL of absolute ethyl alcohol (200
proof, 64-17-5, Pharmaco Products Inc, Brookfield, CT) was added to a 1.5
mL centrifuge tube. The dulcitol was used as an internal standard. This
mixture was vortexed and was then centrifuged using a Beckman Microfuge II
centrifuge, at 400 XG for 10 minutes. The supernate was collected and the
precipitate was discarded. The supernate was evaporated under nitrogen until
dry. Each sample was then derivitized by adding 100pL of 0.49 butyl-boronic
acid (16, 324-4 Aldrich Chemical Company, Milwaukee, WI) in ethanol to the
dried sample. The mixture was then mixed in an ultrasonic bath for 10
minutes. An external standard using 6.86 mM sorbitol (S- 7457 SIGMA
Chemical Company, St. Louis, MO) instead of serum was mixed and injected
for each subject using the method described above.
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Gas Chromatography
Gas chromatography was performed using a Hewlett Packard HP-6890 gas
chromatograph (CG) with ChemStation (Agilent. Burlington, MA), using a
Restek RTXl Crossbond 100% dimethyl polysiloxane 30 m, 0.32mmlD10.25
pm DF CG column (Restek Bellefonte, PA). The software used for GC
analysis included ChemStation revision A.08.03 (Agilent, Burlington, MA) and
Teklink 7000 version 2.00 (Tekmar-Dorhman, Cincinnati, OH). Two microliters
of the prepared sample was injected directly into a Hewlett Packard HP-6890
CG. Inlet temperature was 250°C with a 100:l split ratio and 9.52 psi and a
total flow of 195 muminute. The initial oven temperature was 60°C. The
temperature was increased 45°C per minute to 180°C and held for 1 minute.
The temperature was then increased by 10°C per minute to 250°C and held
for 3 minutes. Total run time was 14.67 minutes and equilibration time was 5
minutes. The retention time of the sorbitol was 13.032, and the retention time
of the dulcitol was 13.336. Appendix E contains a sample chromatogram from
the analysis of sorbitol.

Headspace analysis was performed using a Hewlett Packard HP-6890 CG
with Chem station software (Agilent, Burlington, MA) and a Tekmar 7000
Headspace Auto sampler (Tekmar-Dohmann, Cincinnati, OH) using a Restek
Stabilwax Crossbond Carbowax PEG 30 m, 0.32mmlD1 1.0 pm DF CG
column (Restek Bellefonte, PA). The software used for headspace analysis
46

included ChemStation revision A.08.03 (Agilent, Burlington, MA) and Teklink
7000 version 2.00 (Tekmar-Dorhman, Cincinnati, OH). Headspace vials, caps
and teflon septa were purchased from Tekmar-Dorhman (Cincinnati, OH).
Standards were prepared from hexanal (98% 11560-6, Aldrich Chemical Co,
Milwaukee, WI).

Headspace
Rapid headspace gas chromatography (GC) was used to measure hexanal,
which is a product of lipid peroxidation. Elevated levels of hexanal indicate
poor antioxidant status and a high level of lipid oxidation. Decreased levels of
hexanal indicate increased antioxidant status. Hexanal could be used as a
marker of compliance in this study because the cranberry powder has high
antioxidant activity. Subjects who consistently take the cranberry capsules
should have decreasing levels of hexanal during the study. The method used
was based on work completed by Frankel et al. (57, 58). External standards
were run each day the samples were analyzed. Five standards were analyzed
to form a standard curve for analysis and consisted of a 1 mL sample of 50
pM, 25 pM, 12.5 pM, 6.25 pM and OpM hexanal. For each sample of serum, 1
mL of serum was placed in a 22 mL headspace vial and sealed. Vials were
stored in the refrigerator at 4°C until ready to be analyzed. Each sample was
placed in the carrousel when the previous sample was loaded. Samples were
held at a temperature of 50°C for 2 minutes. Platen temperature was 100" C,
platen equilibrium time was 5 minutes, and sample equilibrium time was 10

minutes. The sample was mixed for 1 minute at a power of 1, and then
allowed to stabilize for 1 minute. The vial pressurization time was 0.25
minutes, the pressure equilibrate time was 0.25 minutes, the loop fill time was
0.25 minutes and the loop equilibrate time was 0.20 minutes. The sample
loop temperature was 65" C and the line temperature was 65" C. One
injection was completed per sample and the GC cycle time was 15 minutes.

Gas Chromatography
Initial GC temperature was 50°C, and initial time was 2 minutes. The
temperature was increased 5°C per minute to 65°C. Inlet temperature was
225°C with a split ratio of 100: 1 and a pressure of 11.9 psi. The run time was
15 minutes. Split flow was 259.6 mUmin and total flow was 265.4 mL per
minute. Detector temperature was 180°C with a hydrogen flow of 40.0 mL per
minute and an air flow of 450 mL per minute. The headspace above a 1 mL
sample was analyzed for hexanal. SYSTAT 9 (version 9, Chicago, IL)
statistical software was used to calculate a standard curve using external
standards discussed previously. The following equation was used to calculate
the amount of hexanal in each sample:

mmol of hexanal = (Area of sample * Area of Curve) + constant.

STATISTICS
All statistical analysis was completed using SYSTAT analytical software
(version 9, Chicago IL). The general linear model and Fisher's Least
Significant Difference test were used for analysis with gender, years since
diagnosis of DM, initial blood glucose, and age group used as factors.
Statistical analysis was not completed on information from the health history
or food frequency questionnaires.

RESULTS
SUBJECT DEMOGRAPHICS
Twelve women and 15 men participated in the Cranberry Diabetes Study.
There were 14 subjects in the cranberry group and 13 in the placebo group.
Ages of the subjects ranged from 20 years to 80 years. The mean age of
subjects in the study was 55 years. Subjects had been diagnosed with DM
anywhere from 4 months to 408 months prior to participation in the study.
Only ten of the twenty-seven subjects had initial fasting blood glucose levels
greater than 7.0 mmol1L (range 4.4 to 13.2 mmol1L). A fasting blood glucose
level less than 7.0 mmoVL indicates that blood glucose and DM were well
contmled at the beginning of the study.

Nine of the subjects were not taking any prescription medications during the
study. Other subjects were taking antihyperlipidemic, antihypertensive,
antianxiety, antidepressant and antiarthritic medications. Nineteen of the
subjects exercised 2 or more times per week, one exercised once per week
and seven exercised rarely or never. Tables 10 and 11 have complete subject
demographic information.

Analysis of the food frequency questionnaires indicated that only three
subjects consumed 3 servings of fruits and 3 servings of vegetables daily
(Tables 12 and 13). Average intake of fruit was 1.6

+ 1.3 servings per day,

Table 10: Cranberry Group Health History Questionnaire Results
Subject
CROl

Gender

Age
(years)

F

34

Initial Bbod
Glucose
(mddl)
< 7.0

,
CR02

F

66

< 7.0

CRM

M

49

r7.0

CR05

F

75

r7.0

CR07

M

CRO9

--

< 7.0

M

69

< 7.0

CR10

M

49

< 7.0

CRl1

M

80

r7.0

CR13

M

54

< 7.0

I

M

1

57

Supplements

Exerciw

Type of
Exercise

Family History of
DM

NIA

Rarely

Walking

NIA

24
(0-2 years)
84
(>5 years)
67
(r5 years)

Advil

2x week

Aerobics
PT
Weights

Grandfather

NIA

Multl vitamin
Vimin C
Muili vitamin

Antlhyperlipldemic
Antihypertensive

Aspirin

MUMvitamin

3x week

Antihypertensive (2)

NIA

NIA

3x week

Diuretic
Antihypertenslve(2)
ACE InhlMtor
Anitarrhythmk
Anticoagulant
Antidepressant
Antihypertensive
Antihyperlipidemk
Antihypertensive

NIA

Fish oil

3x week

Walking,
Aerobics
Swimming

Grandmother

Aspirin

NIA

5x week

Father

Baby
aspirin

VimlnA
Vitamin C
Wtamin E
NIA

NIA

Bicycling
Weights
NIA

Rarely

NIA

Antacid
Antltwshre
ACE inhibitor
Thyroid Hormone
Antiyperlipiimic
AnUartMtic
ACE Inhibitor
Thyroid Hormone
NIA

,

I

r7.0

CR16

F

49

r7.0

CR17

F

49

< 7.0

CR23

F

58

r7.0

72
(>5 years)
408
(r5 years)

65
(>years 5)
24
(0-2 years)

1
1

24
(0-2 years)
18
(0-2 years)
134
(>5 years)
1Om
(0-2 years)
36
(2-5 years)
36

1
I

NIA
NIA

I

NIA
NIA

I

NIA

I

Daily

Mother
Grandfather
NIA

Walking
Swimming
tine dandng
Walking

I

Walking

NIA

NIA
Grandmother

I

I

Siblings

1x week

Yoga
Walking
Swimming
Walking,Yoga
Gym

Mother

Daily

Walking

NIA

NIA

NIA

NIA

Daily

Antihypertensive
Antidepressant
Thyroid Hormone
ACE inhlbir
Antihyperlipidemic

NIA

Calcium

2xweek

Aspirin

Vitamin E

D
-MUMVitamin
M
Aspkln
59
< 7.0
vitamin, B6
CR26

NIA = Not applicable

3x week

~
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CRl5

Over the
Counter
drugs
NIA

Preecriptkm
Medications

Months
Since
Diagnosis
16
(0-2 Years)

NIA
NIA

Table 12: Cranberry Group Food Frequency Questionnaires
'Subject
Fruit
Vege ETOH ( CJ
Red Fruit
Total Fruit
Red Vege
Total Vege
D W D W
D W M Y D W M Y D W M Y D W M Y
Year
-- - 40 -- 14 4 65 - -- - 6 -- 6 6 98
--2 1 0 1
8
CROl

* Servings /time period
D = Day

Vege = Vegetables,
W = Week

CJ = Cranberry Juice
M = Month

ETOH = Alcoholic beverages
Y = Year

'

Table 13: Placebo Group Food Frequency Questionnaires*
Red Fruit
Total Fruit
' Subject Fruit Vege ETOH CJ
Y
D W M Y D W M
D W D W
-- -- -- -- - 4 3 - 4 28 5 35
CR03

R 14
CR18
CR19
CR20
CR21
CR22
CR24
CR25

Average

,

- -- 4 2 5 -- 10 8 6
-1 5 2
39 -- 1 2 197 -2 20 2
16
53 , 3 6 5 1
-- /10
15 3 / 15 133 28 12 -- /
1 3 - --3
45
-- 2 20 1 1 29 100
-------- 2
- - - I1 - 1 1
1
- - -- 4 20
g 10 45
2 14 2
149
14
---2 845
5
30
2 1 0 1
30
2 81
- -- -- 2 - 1 6 2
2 10 2 10

-

-

--- --

--

---

--

2

8

Servings 1 time period
D = Day

4

16

23

=

-

33

Vege = Vegetables
W week-

0

1

6

16 1

5

19

CJ = Cranberry Juice
M = Month

78

-

Red Vege
Total Vege
Y
D W M Y D W M
-1 -- - - - - 14 --

-- 1 -- -- -- -- 2 -- --

7
3
13 104

3

--

-- -- -- -- 4 22 4---- -- - -- 2 1 - -- -- -- - -- 9 7 15
-- -- -- 2 - 1 10 22
-- -7
-8
----1-25
--

-

0

-

-

0

-

w

0

e

0

-

1 1 1

ETOH = Alcoholic beverages
Y = Year

12

5

I

and average vegetable intake was 2.8

+ 3.7 servings per day. Seventeen of

the subjects consumed cranberry juice at least once per year (range 0 to 365
servings per year). The average consumption of cranberry juice was 35

+ 98

servings per year. Ten of the subjects drank alcohol (range 0 to 156 servings
per year).

Cranbeny Group
The cranberry group consisted of six females and eight males (Table 10).
Ages ranged from 34 to 80 years. The mean age of subjects in the cranberry
group was 57 years. Eight of the subjects in the cranberry group were over
the age of 50. Six of the subjects had initial blood glucose levels greater than
7.0 mmoUL, and eight had normal blood glucose levels. Six of the subjects
had been diagnosed with DM less than 2 years before the study (range 10 to
24 months). Two subjects had been diagnosed with DM 2 to 5 years prior to
participation in the study (both 36 months). The remaining six subjects in the
cranberry group had been diagnosed with diabetes more than 5 years prior to
participating in the study (range 65 to 134 months). The mean number of
months since diagnosis for the cranberry group was 73

+ 102 months. Four of

the subjects in the cranberry group exercised less than once per week, ten
exercised more than twice per week, and four of the ten who exercised more
than twice per week exercised 5 or more days per week.

Four of the subjects in the cranberry group were not taking any prescription
medications during the study. Eight subjects were taking a diuretic, an
angiotensin converting enzyme (ACE) inhibitor, or another type of
antihypertensive drug. Four of the subjects were on cholesterol lowering
drugs. Six of the subjects in the cranberry group took Advil or aspirin
regularly. No other over the counter drugs were taken regularly by subjects in
the cranberry group. Eight subjects in the cranberry group took some form of
dietary supplement regularly. Participants were asked to refrain from using
antioxidant supplements for 2 weeks prior to and during the study. Four
subjects were taking a multivitamin daily, two were taking vitamin C, and two
were taking vitamin E. Fish oil, vitamin A, calcium, and folic acid were taken
by one or more subjects.

The food frequency questionnaires indicated that the majority of patients in
the study did not eat adequate amounts of fruits and vegetables (Table 12).
Only one subject in the cranberry group consumed at least 3 servings of fruit
daily and only four subjects consumed 3 or more servings of vegetables daily.
Only one subject in the cranberry group consumed 3 servings of fruits and 3
servings of vegetables per day.

Placebo Group
There were six females and seven males in the placebo group (Table11).
Subjects ranged from age 20 to 67. The mean age of subjects in the placebo
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group was 50

+ 58 years. Nine of the subjects in the placebo group were over

the age of 50. Four of the subjects had initial blood glucose levels greater
than 7.0 mmoVL. The remaining nine subjects had normal blood glucose
levels initially. Six of the subjects had been diagnosed with DM less that 2
years prior to participation in the study (range 4 to 18 months), five had been
diagnosed 2 to 5 years prior (range 28 to 60 months), and two subjects had
been diagnosed more than 5 years prior to the study (range 132 to 210
months). The mean number of months since diagnosis was 50 months. Three
of the subjects in the placebo group exercised less than twice per week, and
nine of the subjects exercised more than twice per week, with three of the
nine exercising 5 or more days per week.

Five of the subjects in the placebo group were not taking prescription
medication during the study. Only three subjects in the placebo group were
taking antihypertensive medications and only two were on cholesterol
lowering drugs. Four of the subjects in the placebo group took Tylenol or
aspirin regularly, and one of these subjects took Benadryl regularly. No other
over-the-counter drugs were taken regularly by subjects in the placebo group.
Nine of the subjects in the placebo group were taking one or more dietary
supplements. Prior to the study, six subjects were taking a multivitamin, four
were taking calcium, two were taking vitamin El and others were taking
gincoba, chromium, glucosamine, or fish oil supplements. During the study
these subjects were required to refrain from taking vitamin E and chmmium.
57

Results from the food frequency questionnaires (Table 13) indicated that
three subjects in the placebo group consumed 3 or more servings of fruit daily
and four subjects consumed 3 or more servings of vegetables per day. Two of
these subjects consumed 3 servings of fruit and 3 servings of vegetables per
day.
BLOOD ANALYSES
Fasting Blood Glucose
There were no statistically significant differences in blood glucose levels
between the cranberry group and the placebo group when subjects were
grouped simply by treatment or gender. When subjects were grouped by
initial blood glucose levels, differences were seen between subjects in the
cranberry group with initial blood glucose levels greater than 7.0 mmol/L
compared to patients in the placebo group with initial blood glucose levels
less than 7.0 mmol/L. There were no significant differences when comparing
the cranberry group with initial blood glucose levels less than 7.0 mmol/L to
the placebo group with initial blood glucose levels less than 7.0 mmoVL, or
when comparing the cranberry group with initial blood glucose levels greater
than 7.0 mmol/L to the placebo group with initial blood glucose levels greater
than 7.0 mmoVL.

When subjects were grouped by years since diagnosis of DM, there was not a
significant decrease in blood glucose levels from week 0 to week 12 (Table
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14), but blood glucose levels were significantly lower (p = 0.036) in the
cranberry group than the placebo group for patients who had been diagnosed
with DM more than 5 years prior to participating in the study. There were no
significant differences in blood glucose levels in patients who had been
diagnosed with DM less than 2 years, or 2 to 5 years prior to participation in
the study.

Table 14: Mean Fasting Glucose Levels by Years since Diagnosisa
Treatment

Years Since

Time (Weeks)

N

Diagnosis

0

6

12

Cranberry

0-2

6

6.6f1.9

6.6f 1.7

Placebo

0- 2

2

6.1k0.8

7.1f1.9

+
6.4+ 0.7

Cranberry

2-5

6

6.9f 0.4

7.3f 0.7

6.6f 0.8

Placebo

2- 5

6

7.5f 3.5

7.4 2.9

6.8f 2.4

Cranberry

>5

5

7.1f1.7

6.5f1.4

6.6f1.2*

Placebo

>5

2

6.621.1

7.4f 0.4

8.1 f 2.0*

+_

6.3 0.9

mmoVL, 1 reading per person per time
= Blood glucose signifiwntly I& (p = 0.036) in cranbemy group than placebo group.

In patients less than 50 years of age, serum glucose levels decreased
significantly (p = 0.030)in the cranberry group compared to the placebo group
at week 6 (Table 15). This was not the case at week 12. Serum glucose

levels decreased 7% in the cranberry group and increased 33% in the
placebo group at week 6 in subjects less than 50 years of age.

In patients older than 50 years, there were no significant differences between
the cranberry group and the placebo group either at week 6 or at week 12.
Mean serum glucose level decreased 0.5 mmol/L between week 0 and week

12 in the cranberry group and 0.3mmol/L in the placebo group.

Table 15: Mean Serum Glucose Levels by Age Groupa
Treatment Age Group

a

Time (weeks)

N

0

6

12

+

Cranberry

60

6

7.0 1.8

6.5 1.5' "

+

6.9 1.1

+

Placebo

60

4

7.6k3.8

9.1k2.8'"

8 .3+1.8

Cranberry

>50

8

6.8k 1.7

6.7 1.5

+

6.3k 1.5

Placebo

>50

9

6.4f 1.2

6.4f 1.2

6.1f 1.2

mmol/L, 1 reading per person per time

'Significant difference (p = 0.030) in blood glucose levels from week 0 to week 6
Glycosylated Hemoglobin
There were no significant differences in HbAlc levels when subjects were
grouped by treatment, gender, age group, or initial blood glucose levels.
Mean HbAlc decreased slightly in women in both the cranberry group and the
placebo group from week 0 to week 6 (Table 16).Both groups increased from
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week 6 to week 12. In males, mean HbAlc decreased in the cranberry group
between week 0 and week 6 and returned to the week 0 value at week 12. In
the placebo group, the mean was the same at week 6 as at week 0, but
increased from week 6 to week 92. From week 0 to week 12 there was a
difference bordering on significance (p = 0.060) for males between the
cranberry group and the placebo group.

Table 16: Mean HbAtc Levels by Gendep

-

Treatment Gender

Time (weeks)

N

0

6

12

Cranberly

F

6

6.2%

+ 1.0

6.1% k 1.0

6.4% f 1.0

Placebo

F

6

6.5% k 1.5

6.3% k 1.3

6.5% k 1.1

+ 1.3 6.5% + 1.1*
M
7
Placebo
7.4% k 1.5"
7.0% + 1.4
7.0% + 1.2
Cranberry

M

8

6.5% k 1.5

6.3%

1 reading per person per time
No significant differences between cranberry and placebo when subjects grouped by gender.
Difference bordering on significance (p = 0.060) for males at week 12 between treatments.

When subjects were grouped by years since diagnosis (Table 17), HbAlc
levels decreased in the cranberry group from week 0 to week 6 (-0.3), and
increased in the placebo group (+0.2) in subjects who had been diagnosed
with DM more than 5 years prior to the study. HbAlc levels decreased
significantly (p = 0.031) in the cranberry group compared to the placebo group
at week 6 in subjects diagnosed with DM more than 5 years before the study.
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Both the cranberry group and the placebo group either had returned to week
0 values or had a slight increase in mean HbAlc levels at week 12 regardless

of time since diagnosis.

Table 17: Mean HbAqc Levels by Years since Diagnosisa
I

Treatment Years Since

I

Diagnosis

1

N

Time (Weeks)
0

+ 0.8

Cranbeny

0-2

6

6.2%

Placebo

0-2

2

5.9% f 0.3

Cranberry

2-5

6

6.3%

Cranbeny

>5

5

6.6%

Placebo

>5

2

I

I

6

+ 0.8
6.0% + 0.2
6.5% + 0.9

6.1%

+ 0.7

+ 1.8
7.2% + 0.2

I

+ 1.4*
7.4% + 0.6*

6.3%

I

1 readim uer person uer time
'significaVidecrease '(p = 0.031) in HbAlc levels in aanbeny group compared to placebo
group.

Fnrctosamine Levels
There were no statistically significant differences in fructosamine levels from
week 0 to week 12 between the cranberry group and the placebo group when
data was analyzed for treatment effects, gender effects, time since diagnosis,
or initial blood glucose levels, but subject age was influential.

Fructosamine levels improved significantly (p = 0.027) in the cranberry group
compared to the placebo group in patients less than the age of 50 from week
0 to week 6, but increased in the cranberry group from week 6 to week 12
(Table 18). There was not a statistically significant difference in fructosamine
levels from week 0 to week 12 in either the group under the age of 50 or the
group over the age of 50.

Table 18: Mean Fructosamine Levels by Age Groupa
Treatment

Age

N

Cranberry

<SO

6

Placebo

<SO

4

Cranberry

>50

8

Placebo

>SO

9

.ime (weeks)

I

~ignifi&ntl~
(p =0.027).lower in cranberry group compared to placebo group at week 6.
No significant differences from week 0 to week 12.

Aldose Reductase Activity

GC analysis of serum sorbitol measured sorbitol in only 6 serum samples,
and all were in the week 0 blood draw. Each sample was measured using 2
duplicates and 2 replicates of each duplicate. Results were not consistent
since none of the results indicated that there was sorbitol in both duplicates
and both replicates. Table 19 has detail of results of sorbiiol analysis.
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Table 19: Aldose Reductase Activity Resultsa
SUB

TRT

Sorbitol

Draw 1

Draw 2
D2

Dl

Dl

R1 R2 R1 R2

D2

R2 R1 R2

CR04

Cranberry

CR05

Cranberry

CR06

Placebo

CR08

Placebo

CR18

Placebo

- - - - - - -- X
X
- - - - - X
- - X - - - - - - - - X

CR21

Placebo

X

X

-

R1

Draw 3
Dl
R1 R2

D2
R1

R2

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - X

b

X lndicates detectable sorbitoi
D Indicates Duplicate
lndicates no sorbitol detected

-

TRT lndicates Treatment
R Indicates Replicate

SUB lndicates Subject

Serum Insulin
There were no statistically significant differences in serum insulin levels
between the cranberry group and the placebo group when subjects were
grouped by treatment, gender, initial blood glucose level, or age group. There
were statistically significant differences in serum insulin levels when patients
were grouped by time since diagnosis of DM.

When subjects were grouped by time since diagnosis of DM, there was an
overall statistically significant difference (p = 0.015) in serum insulin levels
between the treatment group and the placebo group at week 12 (Table 20). At
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week 12,serum insulin levels in patients in the placebo group with diabetes
more than 5 years were significantly higher than in any other group. In the
group that had DM greater than 5 years, serum insulin levels decreased
significantly (p = 0.002)in the cranbeny group compared to the placebo
group.

Table 20: Mean Insulin Levels by Years since Diagnosisa
I

Treatment Years Since

N

Diagnosis
-

-

-

0

6

12

97f 40

104f63

96 f 53

165f129 270f270

120 k 65

Cranbeny

0-2

6

Placebo

0-2

2

Cranbeny

2- 5

6

72 f 0

81 st 55

63 k 38

Placebo

2- 5

6

114f96

110f91

73 f 37

Cranbeny

>5

5

61 f 33

54f 19

51 f 18*

Placebo

>5

2

120f25

153f21

324k339*"

-

-

Time (Weeks)

'

prnok, 1 reading per person per time
Overall significant decrease (p = 0.015) in cranbeny group compared to placebo group.
'Cranbeny group decreased significantly (p = 0.002) compared to placebo group
"Significantly higher than any other group.

Lipid Levels
There were no statistically significant differences in serum triglycerides, total
cholesterol, LDL, HDL or percent HDL between the cranberry group and the
placebo group when patients were grouped by treatment, gender, initial blood

glucose, or age group. There were significant differences in lipid levels
between the cranberry group and the placebo group when subjects were
grouped by time since diagnosis. Table 21 lists mean lipid levels by
treatment.

Table 21 : Mean Lipid Levelsa
~reatment

Lipid

N

Time (weeks)

0

6

12

Cranberry

Triglycerides

14

If1

2+1

If1

Placebo

Triglycerides

13

2f 1

2+1

2f 1

Cranberry

Cholesterol

14

5f 1

5+1

5f1

Placebo

Cholesterol

13

5+1

5+1

5f 1

Cranberry

LDL

14

4f1

3+1

3+1

Placebo

LDL

13

3+1

3 1

3+1

Cranberry

HDL

14

If0

If0

1 f0

Placebo

HDL

13

1+1

If0

1 +O

a

mmol/L, 1 reading per person per time
No significant differences between cranberry and placebo groups.

Triglycerides
Triglycerides were significantly lower (p = 0.011) in the cranberry group than
the placebo when subjects were grouped by years since diagnosis of DM
(Table 22). Triglyceride levels were highest in the placebo group with DM
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more than 5 years. Among patients with DM more than 5 years, triglyceride
levels decreased significantly (p = 0.002) from week 0 to week 12 in the
cranberry group compared to the placebo group. Triglyceride levels
decreased 16% in the cranberry group and increased 152% in the placebo
group. In the group with DM more than 5 years, triglyceride values decreased
significantly (p = 0.013) in the cranberry group compared to the placebo
group.

Table 22: Mean Triglyceride Levels by Years since Diagnosisa
Treatment

Years Since

I N I

Time (Weeks)

Cranberry
Placebo
Cranberry
Placebo
Cranberry
-

Placebo
t

I

per time
mmolIL, 1 readi~IQ
- .per person
.
Overall cranbeny group decr&sed significantly (p = 0.01 1) compared to the placebo group
from week 0 to week 12.
'Decreased significantly (p = 0.002) in the cranbeny group compared to the placebo group.
"Significantly higher than any other group.

Total Cholesterol

Total cholesterol levels decreased significantly (p = 0.034)from week 0 to
week 12 in the cranberry gmup compared to the placebo group when
subjects were grouped by years since diagnosis of DM (Table 23). Subjects in
the placebo group that had been diagnosed with DM over 5 years ago had
significantly higher cholesterol levels than any other group at week 12. In
subjects with DM over 5 years, cholesterol levels improved significantly (p =

0.007)in the cranberry group compared to the placebo group.

Table 23: Mean Total Cholesterol Levels by Years since Diagnosisa
C

Treatment

Years Since

N

Diagnosis

Time (Weeks)

0

6

12

Cranberry

0-2

6

5f 1

5f 1

5k1

Placebo

0- 2

2

5+1

5+1

5+1

Cranberry

2-5

6

5f1

5+1

5f 1

Placebo

2-5

6

6k1

6k1

6+1

Cranberry

>5

5

6k1

5k1

5 k '1

Placebo

>5

2

4fl

5f1

6fO' "

i

mmolIL, 1 reading per person per time
Overall cranberry group significantly (p = 0.034) lower than placebo group.
Decreased significantly (p = 0.007) in the cranberry group compared to the placebo group.
"Significantly higher than any other group.

a

Percent HDL Cholesterol

From week 0 to week 12, percent HDL improved significantly (p = 0.021) in
the cranberry group compared to the placebo group in subjects who had DM
more than 5 years (Table 24). There were no statistically significant
differences in percent HDL between the cranberry group and the placebo
group in patients that had been diagnosed with DM 0 to 2 or 2 to 5 years prior
to the study.

Table 24: Mean Percent HDL Levels by Years since Diagnosisa
'~reatment

ICranberry

Years Since

/1

N

Time (Weeks)

Diagnosis

0-2

1
Placebo

Placebo

IPlacebo

2-5

I

>5

2

24.9

+ 6.9

23.9 f 9.8

+

16.8 0.6"

1 reading per person per time
'Increased significantly (p = 0.021) n the ranbeny group compared to the placebo group.

Hexanal
The results of analysis of serum hexanal were not sufficient to draw any
conclusions. Six subjects in the cranberry group and 2 subjects in the placebo
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group had measurable serum hexanal levels at one of the 3 blood draws.
None of the subjects had measurable levels of serum hexanal at more than
one of the blood draws. Table 25 contains the results of the hexanal analysis.

Table 25: Hexanal Resultsa

Draw

Treatment

Hexanal (mmol)

CROl

1

Cranberry

1.512

CR02

1

Cranberry

1.720

Cranberry

4.766

Cranberry

4.830

Subject
-

2

CR15
CR16

1

2

1

Cranberry

I

4.797

CR5

3

Cranberry

4.183

CR25

2

Placebo

-0.032

1

I

3

CR21
a

I

I

2.810

Placebo

I

Data insufficient to draw conclusions

I

DISCUSSION
HUMAN SUBJECTS
Recruiting, Scheduling, and Compliance

The most challenging aspect of this study was working with human subjects.
Recruiting, scheduling, and compliance were all important issues in carrying
out this investigation. Many of the people who replied to the recruitment ads
were not eligible for the study due to medical complications or use of
hypoglycemic medications. A large hospital in the area was recruiting for a
similar study at the same time, so it was difficult to find eligible subjects. The
fact that blood could be drawn only at Cutler Health Center on the University

of Maine campus also affected recruiting. Several participants had to travel
from rural areas of Maine to participate in the study, while others decided not
to participate due to the need to travel. In the end, the number of subjects
was three short of the goal of thirty subjects.

Scheduling was also challenging for several reasons. It was necessary to
schedule blood draws on days that were convenient for the staff at the
phlebotomy lab. Whenever possible several subjects were scheduled to have
blood drawn on the same day, so it was necessary to schedule extra staff at
the phlebotomy lab. Most of the subjects were employed, so it was necessary
to schedule blood draws around their work schedules. The subjects also
needed to fast for 12 hours prior to the blood draw, so blood draws were
scheduled in the mornings.

Compliance may have been an issue in this study. Subjects were called or
emailed periodically to remind them to take the capsules, but there was no
method in place to ensure that subjects took the capsules. Hexanal could
have been used as a marker of compliance due to its high antioxidant activity;
however, the results were not sufficient to draw conclusions. Unused
capsules were not returned at the conclusion of the study, which would have
been one measure of subject compliance. Several of the subjects had
improvements in laboratory values at the week 6 blood draw, but did not
sustain the improvements at week 12. This could be due to decreased
compliance during the last 6 weeks of the study, or due to other unknown
factors.

Subject Demographics

Differences between the subjects on the cranberry treatment and the subjects
on the placebo may have affected the results of this study. Subjects were
randomly assigned to either the cranberry group or the placebo group, and
the demographics of each group were very different. The results might have
been different if subjects had been matched between the cranberry group and
the placebo group instead of randomly assigned to a group. If the two groups
had been more similar, it is likely we would have seen more significant
results.

Patients in the placebo group were likely healthier overall than patients in the
cranberry group. Overall the patients in the placebo group were younger and
had been diagnosed with DM more recently than subjects in the cranberry
group. The mean age of the placebo group was 4 years younger than the
cranberry group, but the number of subjects over the age of 50 was
comparable in both groups (8 cranberry, 9 placebo). The mean number of
months since diagnosis was 23 months less in the placebo group than in the
cranberry group. There were six subjects in each group that had been
diagnosed with DM less than 2 years prior to participation in the study, but the
cranberry group had five subjects who had DM for more than 5 years,
compared to only two in the placebo group. Since DM is a progressive
disease, it is likely that patients who have had DM longer will have more
complications from the disease, and they may be less healthy. The subjects
who have had DM for a shorter time are likely to have lower values on
laboratory analyses than subjects who have had the disease longer, and lab
values are more likely to be stable throughout the study.

There were fewer subjects in the placebo group with elevated blood glucose
levels initially than in the cranberry group. Six subjects in the cranberry group
had elevated blood glucose levels at week 0 compared to four in the placebo
group. It is likely that cranberry supplementation will have more of an effect
for patients with elevated blood glucose levels, but because a larger number

of subjects in the placebo group had normal blood glucose levels, statistical
significance may be difficult to see.

There were fewer subjects in the placebo group taking prescription
medications. Eight subjects in the cranberry group were being treated for high
blood pressure compared to three in the placebo group. Four subjects in the
cranberry group were taking medication for high cholesterol compared to two
in the placebo group. This may be due to the increase risk of macrovascular
complications associated with DM.

The higher number of subjects with

hypertension and hyperlipidemia in the cranberry group may have been
related to the number of subjects who had DM for a longer period.

Intake of fruits and vegetables was poor in both groups. One subject in the
cranberry group and two in the placebo group consumed 3 servings of fruits
and 3 servings of vegetables per day. One subject in the cranberry group
compared to three in the placebo group consumed 3 servings of fruit per day,
and four subjects in each group consumed 3 servings of vegetables per day.
Serving sizes on the food frequency questionnaire were larger than those
used in diabetic carbohydrate counting and the Food Guide Pyramid, so use
of a different measure may have resulted in improved fruit and vegetable
intakes.

Three subjects in the cranberry group consumed cranberry juice occasionally,
compared to seven in the placebo group. There was little consumption of red
colored fruits and vegetables in either group. The red fruits and vegetables
have anthocyanin and flavonoid contents similar to cranberries. Subjects that
normally have a high intake of cranberry juice and other fruits and vegetables
that contain anthocyanins and flavonoids may have seen less benefit in this
study due to the fact that they were already consuming a beneficial diet.

A very diverse group of subjects participated in this study. The wide range of

initial blood glucose values and levels of control of the disease may have
affected the ability to see statistical significance when analyzing data. If all
subjects had elevated blood glucose levels at the beginning of the study, the
effect of cranberry supplementation may have been more significant.

INDICATORS OF CONTROL OF DIABETES MELLITUS
ACdose Reductase ActiiCty
The method used to analyze sorbitol in serum samples as an indicator of
aldose reductase activity was not sufficiently sensitive. It is likely that more
subjects had sorbitol present in their serum than was measured: All samples
that had measurable sorbitol were in the week 0 blood draw, and results were
not consistent between duplicates and replicates. It is not likely that sorbitol
decreased in the placebo group from week 0 to week 12, especially in
subjects whose blood glucose levels and HbAlc levels increased. Some

chromatograms showed small peaks at the sorbitol retention time, but the
peaks were too small to measure. Use of a different method or refinement of
the current method would have resulted in more precise measurement of
sorbitol in the serum samples. High concentrations of sorbitol are not normally
present in the serum, so it is not surprising that the results were insufficient. If
red blood cells had been used to analyze sorbitol instead of serum, the
results would likely have been more significant.

Glucose, HbAIC, Fructosamine, and Insulin Levels
In most of the analyses performed as indicators of DM control, significant
differences were seen only when data was grouped by length of time since
diagnosis of DM and only in the group that had the disease the longest. More
pronounced results are likely to be seen with cranberry supplementation in
individuals who have had the disease the longest because they may have the
higher glucose levels that result in more damage from hyperglycemia. The
higher glucose levels would lead to protein glycosylation.

Grouped by Treatment and Gender
There were no significant differences in blood glucose, HbAlc, fructosamine,
or insulin levels when subjects were grouped simply by treatment or when
they were grouped by gender. This is likely due to the fact that many of the

subjects already had good control of their DM at the beginning of the study.
Seventeen subjects (63%) had normal blood glucose levels initially. When
glucose levels are in the normal range, it is less likely that an improvement
will be seen. If the initial screening process had excluded subjects with
normal fasting blood glucose levels, it is likely that cranberry supplementation
would have shown more benefit overall.

As discussed earlier, protein glycoslylation occurs in relation to the level of
hyperglycemia, so subjects with good control of DM have less glycosylation of
protein. This would affect results of the HbAlc and fructosamine analyses.
Only two subjects in the cranberry group and three in the placebo group had
HbAlc levels greater than 7% initially. One in each group had HbAlc levels

greater than 9%. With subjects with well controlled DM, there is little
opportunity for improvement in laboratory values.

DM may affect insulin levels in two ways. As discussed earlier, type 2 DM
may be due to decreased pancreatic production of insulin, decreased insulin
sensitivity in the cells of the body, or a combination of both problems. In
subjects with decreased insulin production, serum insulin levels decline as the
disease progresses. In subjects with decreased insulin sensitivity, insulin
levels increase as the disease progresses. Most subjects in this study had
normal insulin levels throughout the study. Only two subjects had elevated
insulin levels at week 0,four had elevated insulin levels at week 6, and only

one subject had elevated insulin levels at week 12. The high number of
subjects with normal insulin levels suggests that there would be little
improvement in insulin levels especially when subjects are grouped by
treatment or by treatment and gender.

The diversity of the subjects is also a factor when analyzing data. The age
range of subjects and the variability of control of glucose levels decreased
likelihood of seeing significant differences when subjects were grouped
simply by treatment or by treatment and gender.

Grouped by Years since Diagnosis

Most statistical significance in data analysis was seen when subjects were
grouped by time since diagnosis. Blood glucose levels and insulin levels were
significantly higher at week 12 in subjects in the placebo group who had DM
more than 5 years. This is to be expected because DM is a progressive
disease. The longer a person has DM, the higher the degree of insulin
insensitivity. As insulin sensitivity decreases, the body must produce more
insulin to control blood glucose levels. Eventually the pancreas is unable to
produce enough insulin to control glucose levels, and oral hypoglycemic
drugs or exogenous insulin becomes necessary.

When subjects were grouped by years since diagnosis of DM, HbAic levels
decreased significantly in the cranberry group compared to the placebo group

at week 6 in the group that had DM the longest. Mean HbAlc levels were
highest in the placebo group that had DM more than 5 years. The longer a
person has DM, the more likely that elevated glucose levels will cause protein
glycosylation and the subsequent damage. This is the group that will benefit
most from inhibition of aldose reductase and non-enzymatic protein
glycosylation.

The fact that HbAlc levels decreased at week 6 and then increased at week
12 may have been due to decreased compliance in the last 6 weeks of the
study or it may have been due to a degradation of anthocyanins in the
cranberry powder as the study progressed. It is not known how the
processing of the cranberry powder used in this study affected the
anthocyanins and flavonoids. It would have been beneficial to measure the
anthocyanin and flavonoid content of the cranberry powder at the beginning
of the study and again at the end of the study. This would be an indication of
whether the changes seen from week 6 to week 12 were due to degradation
of anthocyanins and flavonoids.

As with other indicators of severity and control of DM, significant differences

in insulin levels were found only when subjects were grouped by time since
diagnosis of DM. There was an overall significant difference in insulin levels,
with subjects in the placebo group that had DM the longest having
significantly higher insulin levels than any other group. This is expected due

to the increase in insulin sensitivity as the disease progresses. It should be
noted that there was a wide range of insulin levels and the standard
deviations were extremely high. A few subjects had highly elevated insulin
levels.
Another important factor in analyzing data when subjects were grouped by
years since diagnosis is that there were only two subjects in the placebo
group with DM more than 5 years. One of the subjects in this group had near
normal glucose and HbAlc levels initially (5.8 and 7.3 respectively) but had
large increases from week 0 to week 6 (glucose 5.8 to 7.1 and HbAlc 7.3 to
7.8), and from week 6 to week 12 (glucose 7.1 to 9.5 and HbAlc 7.8 to 8.7).
The other subject in this group had initial glucose and HbAlc values in the
desirable range and decreased by week 12. The small number of subjects in
this group and the diversity in the control of the disease may have influenced
results of the study.

Grouped by Initial Glucose Levels
When subjects were grouped by initial glucose levels, differences were seen
in glucose levels at week 12. Glucose levels were significantly lower in
cranberry subjects with initial glucose levels greater than 7.0 mmolIL, than in
the placebo group with initial glucose levels less than 7.0 mmol1L. This is
likely due to the fact that subjects with elevated glucose levels are more likely
to see improvement in these values, while subjects with normal glucose levels
remain stable.

Grouped by Age
One might think that blood glucose, HbAlc, fructosamine and insulin levels
would be higher in older subjects, but that was not the case in this group of
subjects. Mean glucose levels were not significantly higher in the group of
subjects older than 50 years. This could be due to the fact that only three
subjects over the age of 50 had DM for more than 5 years, and five subjects
under the age of 50 had DM for more than 5 years. Results of this study
indicated that age did not influence the effect of cranberry supplementation on
glucose levels, but time since diagnosis did. This is likely due to the fact that
the subjects who had DM the longest were not necessarily the oldest
participants.

Hexanal
Headspace analysis of hexanal concentration of serum samples was used to
measure

lipid

oxidation

and

antioxidant

status

with

cranberry

supplementation. The method was not effective in this study. It is possible
that if there had been another standard at a lower concentration (3.125 pM),
more subjects would have had detectable amounts of hexanal measured in
their serum. Due to the poor outcomes of this analysis, the effect of cranberry
supplementation on oxidant status and lipid oxidation is unknown.

Triglycerides, Total Cholesterol, LDL, HDL and Percent HDL
Significant differences were seen in lipid levels only when subjects were
grouped by time since diagnosis of DM, and then only in triglyceride levels,
total cholesterol, and percent HDL. In all cases the differences were seen in
the group who had DM for more than 5 years. Subjects in the placebo group
who had the disease more than 5 years had higher lipid levels than any of the
other groups. Mean triglyceride and total cholesterol levels were stable from
week 0 to week 12 in all groups except those with DM more than 5 years. In
this group the mean values decreased for subjects on the cranberry treatment
and increased for subjects on the placebo treatment.

The changes in triglyceride levels are likely due to the correlation between
hyperglycemia and elevated triglycerides. As blood glucose levels increase,
triglyceride levels increase proportionately. As discussed previously, one of
the two subjects in the placebo group with DM for more than 5 years had
significant increases in glucose levels during the 12 week study. It is likely
that the hyperglycemia resulted in the elevated triglyceride levels.

Changes in percent HDL were likely a result of changes in total cholesterol
levels. Percent HDL is calculated by dividing HDL by total cholesterol and
multiplying by 100, so a change in total cholesterol will impact percent HDL
independent of changes in HDL levels.

PREVIOUS WORK
There have not been any previous in vivo studies investigating cranberry
supplementation to decrease the side effects of DM in humans. The results of
this study correspond with research previously done in rats and in vitro,
investigating the effect of supplementation of anthocyanins and flavonoids on
diabetes. Jankowiski et al. (45) investigated the effects of anthocyanin
pigments from red wine on blood and urine glucose levels in 80 rats. There
was a decrease in glucose concentrations with supplementation of
anthocyanins. In the current study, there was a decrease in blood glucose
levels in patients on the cranbeny treatment who had DM the longest and
who had elevated blood glucose levels initially.

Keenoy and De Leeuw (44) investigated the effect of a flavonoid preparation
on protein glycosylation and antioxidant status in twenty-eight subjects with
type 1 DM in a three month study. There was a significant decrease in HbAlc

levels with flavonoid treatment. In the current study, HbAlc levels decreased
in the group of subjects who had DM over 5 years and in the group with
elevated glucose levels initially. Daflon 500, the flavonoid preparation used in
the Keenoy and Le Leeuw study, contains a much higher concentration of
flavonoids than cranbeny juice. Due to the lower concentration of flavonoids
in cranbeny juice, a higher dosage would likely be needed to see the same
effects. If a higher dosage of cranberry juice had been used in the current

study, this might have resulted in significant differences overall between the
cranberry group and the placebo group.

Hamada et al. (40) investigated the effect of epalrestat, a known aldose
reductase inhibitor, in subjects with type 2 DM who had been taking the drug
for 2 months. There were decreases in the end products of protein
glycosylation (sorbitol, fructose, triosephosphats, TBARS and 3-DG levels),
but no changes in plasma glucose or HbAlc levels. In the current study, there
were decreases in glucose and HbAlc levels in subgroups of the subjects, but
end products of protein glycosylation were not measured, and analysis of
sorbitol was unsuccessful.

Pedersen et al. (52) conducted a study comparing the antioxidant capacity of
consumption of cranberry and blueberry juice in the plasma of nine female
volunteers. Results indicated that consumption of blueberry juice did not
significantly increase plasma concentrations of total phenols or vitamin C as
cranberries did, though bluebemes have a higher concentration of phenolic
substances than do cranbemes. Cranberry juice is fortified with vitamin C and
the blueberry juice used in this study was not. Researchers question how
readily the phenols were absorbed in the gut. Consumption of cranberry juice
did lead to significant increases in total phenols and a 30% increase in serum
vitamin C concentration. It is possible that increases of total phenols in serum
following cranberry juice consumption was primarily due to the increased

vitamin C levels. If anthocyanins are not readily absorbed, then it is possible
that the dosage used in the Cranberry Diabetes Study was insufficient to see
significant results. It is likely that a higher intake of cranberry juice would have
resulted in more significant differences.

The form of cranberry juice may also have been a factor in the results of this
study. The processing of the Decas cranberry powder may have decreased
the anthocyanin content of the product. Liquid cranberry juice was used in
Pederson's study, which may have contained more anthocyanins and
flavonoids than the powder that had additional processing. The heat used in
processing the cranberry juice into powder may have caused degradation of
the anthocyanins and other flavonoids in the juice. This would decrease the
antioxidant activity of the powdered juice.

A study conducted by Vincent et al. (38) investigated the ability of vitamin C to

inhibit aldose reductase in human erythrocytes. Results indicated that
ascorbic acid decreased intracellular sorbitol concentrations by 25 to 45 %.
Vitamin C may be beneficial for people with diabetes, and most commercial
cranberry juice cocktail has high levels of vitamin C. Many of the subjects in
the placebo group did not consume fruits and vegetables high in vitamin C.
Subjects who did not consume adequate vitamin C might have benefited from
the small amount of vitamin C in the placebo, which would have masked the
effects seen for patients on the cranberry treatment.

CONCLUSIONS
The results of this study suggest that cranberry supplementation may be
beneficial for patients with type 2 DM who have poor control of glucose levels,
but further research must be conducted. The subjects in the cranberry group
were very different than in the placebo group. Differences in age, control of
DM, and time since diagnosis between the placebo group and the cranberry
group likely affected the results of this study. The number of subjects with
normal blood glucose and HbAic levels was likely also a factor in the results
of this study.

The form of cranberry juice may have affected the results of this study as
well. It is unknown how the bioavailability of the spray dried cranberry powder

used in the study compares to commercial cranberry juice cocktail. The
processing method used for the Decas cranberry powder may have affected
the anthocyanin and flavonoid content of the product. It is possible that using
liquid cranberry juice or raw cranberries might have produced different
results. The anthocyanins in the cranberry powder may also have degraded
throughout the course of the study. This would explain the decreases in
laboratory values at week 6 and the increases at week 12.

There is a need for further research in this area. Future research should focus
on subjects with hyperglycemia, because these are the subjects that are likely
to have more of the side effects that are associated with DM. It is also

important to investigate the correct dose of cranberry juice. In this study all
subjects received the same dose regardless of body weight, but people with a
larger body mass would need a higher dosage than smaller individuals to see
effects of cranberry supplementation. Investigation of how supplementation
with whole cranberries or cranberry juice differs from supplementation with
juice or powders is also important because processing may affect the
anthocyanins found in cranberries.
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APPENDICES

APPENDIX: A
Consent Form

Information About Study:
I am invited to participate in a research study entitled 'Can Cranberry

Supplementation Reduce Risks for Diabetes?" conducted by Dr. Mary Ellen
Camire and Belinda Chambers at the University of Maine Department of Food
Science and Human Nutrition. This preliminary study is designed to investigate
the potential health benefits of cranberry juice for people with Type 2 diabetes.
The study is one in which there will be two treatment groups. One group will be
taking cranbeny capsules and one group will be taking a placebo or control. Only
the primary investigator will know who is taking the cranbeny capsules and who
is taking the placebo. This study is sponsored by the Cranbeny Institute and the
Wisconsin Cranbeny Board.

Procedure:
I have been asked to consume six capsules each day for 12 weeks. I will need to

take two capsules in the morning, two capsules midday and two capsules with
my evening meal. Each capsule contains 0.123 grams of sugar. The gelatin
capsules contain either spray dried cranbeny juice powder made with
magnesium hydroxide, (from Decas Cranbeny Products Inc.) or a placebo
containing cellulose, ascorbic acid, fructose, sucrose magnesium hydroxide and
food coloring. The capsules are made from gelatin; I do not have a dietary
aversion to eating gelatin. If I have difficulty swallowing the capsules, Ican open
the capsules, dissolve the powder in water, and drink the mixture, or I can mix
97

the powder with yogurt or another food and eat it that way. As part of the study I
will be asked to complete a health history and a food frequency questionnaire.
This questionnaire will contain questions such as "When were you diagnosed
with diabetes?" and "Did (do) your siblings have Type 2 diabetes?" and "How
many servings of fruits and vegetables do you eat each d a p " I should
discontinue use of all vitamin supplements(vitamin El vitamin C, chromium, etc.)
except a multivitamin, at least two weeks prior to the start of the study. I should
not change my normal consumption of blueberries, cranberries and grapes
during the course of study. A sample of my blood will be drawn at the beginning
of the study and again at the sixth week and the twelfth week of the study.

I am at least 18 years old, I am not pregnant, and I am not taking medication for

diabetes, autoimmune, heart, liver or kidney disease. I have Type 2 diabetes and
am controlling my blood sugar with diet alone. My participation in the study is
voluntary. Either myself or the primary investigator may terminate the study at
any time. The supplements that will be given to me are food products. The blood
collection process is no different from one I would experience in a doctor's office
or a hospital laboratory.

Risks 8 Benefits:
There may be some minor bruising from the blood drawing procedure, but the
risk is no different from any other blood drawing procedure. I will be given $150
for my participation in the study, $50 for each blood drawing procedure. I may
receive copies of my lab results if I so desire. I may also have some immediate

health benefits such as decreased oxidation of LDL cholesterol, decreased
retinopathy, nephropathy and neuropathy.

Confidentialitv:
All information and data that are collected in this research project will be kept
confidential and locked in the investigator's office. A number code will be used on
all records and results to ensure confidentiality. Once the final manuscript has
been published, all confidential records will be destroyed.

All records and

personal information about my involvement in this project will be kept
confidential, and my name will in no way be associated with the results of this
project. The results of this project will be released in summary form only.

Contact Information:
If I have any questions I can reach Dr. Mary Ellen Camire or Belinda Chambers
at

(207)

581-3581

at

or

by

email

belinda.chambers@umit.maine.edu

Print
Name:

Date:

Signature:

at

camire@maine.edu

or

APPENDIX B
Health History Questionnaire
Number Identifier:
Date
Age:
A . At what age were you diagnosed with Type 2 diabetes?

2. How long have you had Type 2 Diabetes?

Years

3. Are you taking medication for your diabetes?

Yes
No

4. Are you taking any prescription medications?

Yes

Months

No

If yes, what are you taking?

5. Are you taking any over the counter medications? Yes

No
If yes, what are you taking?

6. Are you taking any dietary supplements?
If yes please list:

Yes

No

7. How often do you exercise?
8. What types of exercise do you perform?

9. During the next 12 weeks, do you plan to begin an exercise program or

increase the amount of exercise you do?
Yes
No
10.

Do any of your family members have diabetes?
Mother
Yes
No
Father
Yes
No
Grandmother
Yes
No
Grandfather
Yes
No
Siblings
Yes
No

APPENDIX C
Food Frequency Questionnaire
1. How many W cup servings of fruit do you eat each day3
each week?
2. How many W cup servings of vegetables do you eat each day3
each week?

3. Do you drink alcohol?
Yes
No
If yes, how many servings of alcohol do you drink daily, weekly monthly or
yearly3
Place a number in the column to indicate how often you drink the alcoholic
beverages below, or put a check in the last column if you never drink the
alcoholic beverages.
Serving Size
Beer

12 ounces

Wine

8 ounces

Hard Liquor

1 ounce

Daily

Weekly

Monthly

Yearly

Never

4. How many times each day, week, month or year do you eat the following fruits?
Place a number in the correct column to indicate how often you eat the listed
fruits. If you do not eat the fruit place a check mark in the never column.

Fruit

Serving Size

Apples

1 apple

Apricots

3 whole
fresh,
1 cup dried

Avocado

1 whole

Bananas

1 whole

Blackbemes

1 cup

Bluebemes

1 cup

Daily

Weekly

Monthly

Yearly

Never

Cantaloup
Cherries

10 cherries

Cranberry
juice

1 cup

Dates

10 dates

---

5. How many times each day, week, month, year do you eat the following
vegetables?
Place a number in the correct column to indicate how often you eat the listed
vegetables. If you do not eat the vegetable place a check mark in the never
column.
r
Vegetable

Serving
Size

Asparagus

4 spears

I Bean sprouts

1 CUP

Beets
Broccoli
Cabbage

I

Carrots

I

Cauliflower
I

1 Celery

,
I

Green beans
Lettuce
Mushrooms

1 Onion

1 Parsnips
1 Radishes
Spinach
I
I

Sweet peppers

Other

1 CUP

'

1 cup

4 radishes

Daily

Weekly

Monthly

Yearly

Never

APPENDIX D

Figure D-I: HPLC Chromatogram

APPENDIX E

Figure E-1: Sorbitol Chromatogram

--

--
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